https://trial.medpath.com/news/brightspring-s-caremed-tapped-for-breakthrough-alzheimer-s-drug-leqembi-distribution 2024-11-06T22:12:15+00:00 weekly 0.7 https://trial.medpath.com/news/sarepta-therapeutics-inc-sec-10-q-report-tradingview 2024-11-06T21:38:57+00:00 weekly 0.7 https://trial.medpath.com/news/lytix-biopharma-first-patient-treated-in-new-phase-ii-clinical-trial-at-radiumhospitalet-in-oslo 2024-11-06T21:30:01+00:00 weekly 0.7 https://trial.medpath.com/news/arcutis-announces-third-quarter-2024-financial-results-and-provides-business-update 2024-11-06T21:26:08+00:00 weekly 0.7 https://trial.medpath.com/news/vanda-pharmaceuticals-reports-third-quarter-2024-financial-results-morningstar 2024-11-06T21:20:36+00:00 weekly 0.7 https://trial.medpath.com/news/regenxbio-reports-third-quarter-2024-financial-results-and-recent-operational-updates 2024-11-06T21:20:35+00:00 weekly 0.7 https://trial.medpath.com/news/soleno-therapeutics-provides-corporate-update-and-reports-third-quarter-2024-financial-results 2024-11-06T21:19:12+00:00 weekly 0.7 https://trial.medpath.com/news/nyxoah-reports-third-quarter-financial-and-operating-results-stock-titan 2024-11-06T21:15:45+00:00 weekly 0.7 https://trial.medpath.com/news/update-predicinecaretm-liquid-biopsy-assay-featured-in-nejm-for-patient-the-manila-times 2024-11-06T21:15:43+00:00 weekly 0.7 https://trial.medpath.com/news/verastem-oncology-reports-third-quarter-2024-financial-results-and-highlights-recent 2024-11-06T21:15:38+00:00 weekly 0.7 https://trial.medpath.com/news/adicet-reports-third-quarter-2024-financial-results-and-provides-business-updates 2024-11-06T21:15:38+00:00 weekly 0.7 https://trial.medpath.com/news/top-in-endocrinology-sotagliflozin-rejected-by-fda-new-lifestyle-intervention-guidelines 2024-11-06T21:14:41+00:00 weekly 0.7 https://trial.medpath.com/news/aurobindo-obtains-fda-ok-for-generic-keflet-drug-store-news 2024-11-06T21:13:39+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-data-shows-lumateperone-delays-schizophrenia-relapse-longer-than-placebo 2024-11-06T21:01:33+00:00 weekly 0.7 https://trial.medpath.com/news/update-predicinecaretm-liquid-biopsy-assay-featured-in-nejm-globenewswire 2024-11-06T21:00:45+00:00 weekly 0.7 https://trial.medpath.com/news/a-first-in-human-open-label-phase-ia-ib-multicenter-multiregional-dose-escalation-study 2024-11-06T21:00:13+00:00 weekly 0.7 https://trial.medpath.com/news/update-predicinecaretm-liquid-biopsy-assay-featured-in-nejm-for-patient-enrollment-in 2024-11-06T20:58:29+00:00 weekly 0.7 https://trial.medpath.com/news/corin-announces-fda-510-k-clearance-for-new-iconatm-femoral-stem-ortho-spine-news 2024-11-06T20:55:43+00:00 weekly 0.7 https://trial.medpath.com/news/merck-and-moderna-launch-phase-3-trial-for-mrna-4157-neoantigen-therapy-plus 2024-11-06T20:51:22+00:00 weekly 0.7 https://trial.medpath.com/news/japan-s-national-cancer-center-selects-paradigm-for-nationwide-clinical-trial-network 2024-11-06T20:37:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approval-withdrawal-of-trodelvy-leaves-fewer-bladder-cancer-options-cure-today 2024-11-06T20:19:33+00:00 weekly 0.7 https://trial.medpath.com/news/around-the-helix-cell-and-gene-therapy-company-updates-november-6-2024 2024-11-06T20:12:25+00:00 weekly 0.7 https://trial.medpath.com/news/a-diabetes-drug-twice-rejected-stumbles-again-but-its-developer-persists-pharmavoice 2024-11-06T20:04:19+00:00 weekly 0.7 https://trial.medpath.com/news/platelet-counts-may-predict-long-term-ultomiris-response-in-ahus-study 2024-11-06T19:35:58+00:00 weekly 0.7 https://trial.medpath.com/news/cassava-s-alzheimer-s-drug-nears-p3-readout-but-sec-scandal-casts-long-shadow 2024-11-06T19:28:51+00:00 weekly 0.7 https://trial.medpath.com/news/a-36-gene-predictive-score-of-anti-cancer-drug-resistance-anticipates-cancer-therapy-outcomes 2024-11-06T19:23:13+00:00 weekly 0.7 https://trial.medpath.com/news/earnings-call-cellectis-reports-robust-cash-reserves-new-r-d-initiatives-investing-com 2024-11-06T19:18:41+00:00 weekly 0.7 https://trial.medpath.com/news/intra-cellular-bolsters-caplyta-data-with-another-phase-iii-win-pharmaceutical-technology 2024-11-06T19:09:32+00:00 weekly 0.7 https://trial.medpath.com/news/nasal-swab-might-predict-how-severe-covid-will-be 2024-11-06T19:00:59+00:00 weekly 0.7 https://trial.medpath.com/news/earnings-call-rhythm-pharmaceuticals-has-reported-a-successful-third-quarter-in-2024 2024-11-06T18:54:30+00:00 weekly 0.7 https://trial.medpath.com/news/study-to-assess-performance-of-cxbladder-test-in-urothelial-carcinoma-surveillance 2024-11-06T18:46:35+00:00 weekly 0.7 https://trial.medpath.com/news/ac102-shows-promise-as-treatment-for-sudden-hearing-loss 2024-11-06T18:43:49+00:00 weekly 0.7 https://trial.medpath.com/news/canada-s-pharma-pipeline-expands-with-12000-new-medicines-as-oncology-leads-trials 2024-11-06T18:41:30+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-dosed-in-ankyra-s-visceral-tumour-study-of-ank-101-clinical-trials-arena 2024-11-06T18:25:03+00:00 weekly 0.7 https://trial.medpath.com/news/milestone-as-pregnant-women-included-in-sa-tb-drug-trial-juta-medicalbrief 2024-11-06T18:20:12+00:00 weekly 0.7 https://trial.medpath.com/news/tetanus-clinical-trial-pipeline-insights-featuring-20-companies-delveinsight 2024-11-06T18:14:57+00:00 weekly 0.7 https://trial.medpath.com/news/qiagen-s-qiastat-dx-meningitis-encephalitis-panel-gains-fda-clearance-for-rapid 2024-11-06T18:04:22+00:00 weekly 0.7 https://trial.medpath.com/news/sa-women-could-have-three-monthly-anti-hiv-ring-by-2026-juta-medicalbrief 2024-11-06T17:50:22+00:00 weekly 0.7 https://trial.medpath.com/news/national-institute-on-aging-invests-an-additional-7-3-million-into-nu-9-northwestern-now 2024-11-06T17:41:18+00:00 weekly 0.7 https://trial.medpath.com/news/dupixent-approved-in-the-eu-as-the-first-and-only-medicine-for-young-children-with-pipelinereview 2024-11-06T17:40:56+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-oral-drug-for-utis-despite-concerns-juta-medicalbrief 2024-11-06T17:40:00+00:00 weekly 0.7 https://trial.medpath.com/news/positive-phase-3-results-evaluating-lumateperone-for-the-prevention-of-relapse-in-schizophrenia 2024-11-06T17:17:29+00:00 weekly 0.7 https://trial.medpath.com/news/study-raises-hopes-of-treating-aggressive-cancers-by-zapping-rogue-dna-the-guardian 2024-11-06T17:15:20+00:00 weekly 0.7 https://trial.medpath.com/news/the-value-of-a-negative-result-uc-davis-health 2024-11-06T17:12:46+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-phase-2-trial-of-leronlimab-for-microsatellite-stable-crc-targeted-oncology 2024-11-06T17:12:01+00:00 weekly 0.7 https://trial.medpath.com/news/fda-pushes-pdufa-date-of-tapinarof-cream-1-for-atopic-dermatitis-to-2025 2024-11-06T17:11:38+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-bla-for-denosumab-biosimilar-hcplive 2024-11-06T17:11:15+00:00 weekly 0.7 https://trial.medpath.com/news/no-benefit-for-extended-lymph-node-surgery-in-mibc-national-cancer-institute 2024-11-06T17:08:44+00:00 weekly 0.7 https://trial.medpath.com/news/domvanalimab-combo-improves-survival-in-advanced-metastatic-nsclc-cancer-network 2024-11-06T17:07:29+00:00 weekly 0.7 https://trial.medpath.com/news/reviva-to-present-positive-speech-latency-data-for-brilaroxazine-in-schizophrenia-from-the 2024-11-06T17:03:47+00:00 weekly 0.7 https://trial.medpath.com/news/cytodyn-gets-us-fda-nod-to-begin-phase-ii-oncology-trial-of-leronlimab-in-patients-with-r-r 2024-11-06T17:00:02+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-lbl-034-for-multiple-myeloma-onclive 2024-11-06T16:49:18+00:00 weekly 0.7 https://trial.medpath.com/news/mi-cancer-seek-receives-fda-approval-as-companion-diagnostic-for-targeted-therapy 2024-11-06T16:49:04+00:00 weekly 0.7 https://trial.medpath.com/news/caris-life-sciences-nabs-fda-approval-for-multicancer-companion-diagnostic 2024-11-06T16:48:50+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-market-authorization-to-light-therapy-system-for-dry-amd-medpage-today 2024-11-06T16:40:45+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-said-to-shuffle-sales-leadership-vertex-records-first-casgevy-sale 2024-11-06T16:38:32+00:00 weekly 0.7 https://trial.medpath.com/news/fidanacogene-elaparvovec-shows-strong-results-in-open-label-phase-3-study 2024-11-06T16:29:56+00:00 weekly 0.7 https://trial.medpath.com/news/lumithera-s-valeda-light-delivery-system-receives-marketing-authorization-from-fda 2024-11-06T16:26:50+00:00 weekly 0.7 https://trial.medpath.com/news/caris-life-sciences-nabs-fda-approval-for-multicancer-companion-diagnostic 2024-11-06T16:19:04+00:00 weekly 0.7 https://trial.medpath.com/news/fda-renews-approval-for-jaguar-s-cid-treatment-in-dogs-investing-com 2024-11-06T16:16:48+00:00 weekly 0.7 https://trial.medpath.com/news/urogen-pharma-reports-2024-third-quarter-financial-results-and-business-highlights 2024-11-06T16:14:36+00:00 weekly 0.7 https://trial.medpath.com/news/once-weekly-semaglutide-reduces-knee-osteoarthritis-pain-body-weight-in-patients-with 2024-11-06T16:13:45+00:00 weekly 0.7 https://trial.medpath.com/news/t-cell-lymphoma-pipeline-insight-analysis-report-2024-globenewswire 2024-11-06T16:03:59+00:00 weekly 0.7 https://trial.medpath.com/news/cracking-the-code-of-dna-circles-in-cancer-stanford-medicine-led-team-uncovers-potential-therapy 2024-11-06T16:01:24+00:00 weekly 0.7 https://trial.medpath.com/news/senhwa-biosciences-announces-first-patient-dosed-in-the-phase-i-ii-study-of-silmitasertib-in 2024-11-06T15:56:38+00:00 weekly 0.7 https://trial.medpath.com/news/inhibiting-viral-rna-cap-methylation-with-anti-viral-molecules-news-medical 2024-11-06T15:53:58+00:00 weekly 0.7 https://trial.medpath.com/news/senhwa-biosciences-announces-first-patient-dosed-in-the-phase-i-ii-study-of-silmitasertib-in 2024-11-06T15:43:23+00:00 weekly 0.7 https://trial.medpath.com/news/precision-medicine-in-sclc-key-biomarkers-revealed-mirage-news 2024-11-06T15:38:52+00:00 weekly 0.7 https://trial.medpath.com/news/addition-of-atezolizumab-plus-bevacizumab-to-chemotherapy-in-advanced-biliary-tract-cancer 2024-11-06T15:33:35+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-renewal-of-canalevia-ca1-jaguar-health-s-drug-for-chemotherapy-stock-titan 2024-11-06T15:31:21+00:00 weekly 0.7 https://trial.medpath.com/news/diamyd-medical-to-present-new-analytical-results-at-diabetes-congress-marketscreener 2024-11-06T15:27:32+00:00 weekly 0.7 https://trial.medpath.com/news/next-generation-oral-serd-in-postmenopausal-women-with-er-positive-her2-negative 2024-11-06T15:13:55+00:00 weekly 0.7 https://trial.medpath.com/news/lundbeck-to-acquire-longboard-drug-store-news 2024-11-06T15:13:36+00:00 weekly 0.7 https://trial.medpath.com/news/zymeworks-doses-first-subject-in-phase-i-trial-of-zw191-for-solid-tumours 2024-11-06T15:11:47+00:00 weekly 0.7 https://trial.medpath.com/news/recce-pharmaceuticals-advances-patient-dosing-to-final-stages-in-phase-ii-trial-for-acute 2024-11-06T15:04:37+00:00 weekly 0.7 https://trial.medpath.com/news/dementia-combo-of-2-active-therapies-may-slow-cognitive-decline 2024-11-06T14:51:21+00:00 weekly 0.7 https://trial.medpath.com/news/recce-pharmaceuticals-advances-patient-dosing-to-final-stages-in-phase-ii-trial-for-acute 2024-11-06T14:44:31+00:00 weekly 0.7 https://trial.medpath.com/news/startup-gives-surgeons-a-real-time-view-of-breast-cancer-during-surgery-mit-news 2024-11-06T14:39:15+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-status-to-seastar-medical-s-scd-investing-com 2024-11-06T14:18:09+00:00 weekly 0.7 https://trial.medpath.com/news/first-of-a-kind-eu-approval-granted-for-eosinophilic-esophagitis-medicine 2024-11-06T14:17:34+00:00 weekly 0.7 https://trial.medpath.com/news/patient-dies-in-beam-trial-of-scd-candidate-company-cites-conditioning 2024-11-06T14:12:18+00:00 weekly 0.7 https://trial.medpath.com/news/in-depth-analysis-showing-robust-diamyd-r-treatment-effects-across-clinical-trials-to-pr-newswire 2024-11-06T14:11:43+00:00 weekly 0.7 https://trial.medpath.com/news/intra-cellular-bolsters-caplyta-data-with-another-phase-iii-win-clinical-trials-arena 2024-11-06T14:10:50+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-for-seastar-globenewswire 2024-11-06T14:04:56+00:00 weekly 0.7 https://trial.medpath.com/news/zollinger-ellison-syndrome-gastrinoma-global-clinical-trials-review-2024-yahoo-finance 2024-11-06T14:03:42+00:00 weekly 0.7 https://trial.medpath.com/news/zollinger-ellison-syndrome-gastrinoma-global-clinical-globenewswire 2024-11-06T13:58:38+00:00 weekly 0.7 https://trial.medpath.com/news/ionis-reports-third-quarter-2024-financial-results-company-announcement-ft-com 2024-11-06T13:49:54+00:00 weekly 0.7 https://trial.medpath.com/news/pharma-firms-showcase-innovative-treatment-for-major-diseases-at-ciie-shine-news 2024-11-06T13:49:44+00:00 weekly 0.7 https://trial.medpath.com/news/urogen-pharma-reports-2024-third-quarter-financial-results-and-business-highlights 2024-11-06T13:40:50+00:00 weekly 0.7 https://trial.medpath.com/news/promising-use-of-lytix-cancer-treatment-in-patients-with-early-stage-melanoma-finansavisen 2024-11-06T13:23:24+00:00 weekly 0.7 https://trial.medpath.com/news/recce-pharmaceuticals-advances-patient-dosing-to-final-globenewswire 2024-11-06T13:23:20+00:00 weekly 0.7 https://trial.medpath.com/news/leal-raises-45m-to-advance-ltx-002-to-clinical-trials-for-als-als-news-today 2024-11-06T13:17:51+00:00 weekly 0.7 https://trial.medpath.com/news/reviva-to-present-positive-speech-latency-data-for-globenewswire 2024-11-06T13:17:08+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotech-to-announce-third-quarter-financial-results-on-globenewswire 2024-11-06T13:17:04+00:00 weekly 0.7 https://trial.medpath.com/news/uniqure-announces-third-quarter-2024-financial-results-and-highlights-recent-company-progress 2024-11-06T13:15:41+00:00 weekly 0.7 https://trial.medpath.com/news/reviva-pharma-to-present-breakthrough-phase-3-schizophrenia-drug-data-at-cns-summit 2024-11-06T13:14:24+00:00 weekly 0.7 https://trial.medpath.com/news/antengene-to-present-results-from-two-late-stage-studies-of-selinexor-signaling-potential 2024-11-06T13:13:47+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-announces-late-breaking-abstract-of-thio-101-updates-selected-for 2024-11-06T13:07:07+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-lugano-trial-explores-eyp-1901-s-potential-to-reduce-treatment-burden-in-wet 2024-11-06T13:06:58+00:00 weekly 0.7 https://trial.medpath.com/news/ionis-reports-third-quarter-2024-financial-results-news-cnhinews-com 2024-11-06T13:04:07+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-data-shows-tev-749-injection-improves-social-function-in-schizophrenia 2024-11-06T13:01:29+00:00 weekly 0.7 https://trial.medpath.com/news/glycomimetics-announces-new-uproleselan-clinical-data-will-be-presented-at-ash-annual-meeting 2024-11-06T13:00:40+00:00 weekly 0.7 https://trial.medpath.com/news/ionis-announces-pivotal-phase-3-trial-design-for-ion582-in-angelman-syndrome 2024-11-06T13:00:34+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-treated-in-new-phase-ii-clinical-trial-at-radiumhospitalet-in-oslo-tradingview 2024-11-06T12:56:00+00:00 weekly 0.7 https://trial.medpath.com/news/praxis-precision-medicines-provides-corporate-update-and-reports-third-quarter-2024 2024-11-06T12:53:24+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-s-balversa-granted-mhra-approval-in-bladder-cancer-pmlive 2024-11-06T12:41:10+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-journey-medical-s-emrosi-to-treat-inflammatory-lesions-of-rosacea-pmlive 2024-11-06T12:40:48+00:00 weekly 0.7 https://trial.medpath.com/news/elevation-oncology-reports-third-quarter-2024-financial-results-and-highlights-recent 2024-11-06T12:36:22+00:00 weekly 0.7 https://trial.medpath.com/news/update-to-the-statistical-analysis-plan-for-notacs-a-multicentre-adaptive-randomised-controlled-trial 2024-11-06T12:36:17+00:00 weekly 0.7 https://trial.medpath.com/news/elevation-oncology-reports-third-quarter-2024-financial-results-and-highlights-recent 2024-11-06T12:35:44+00:00 weekly 0.7 https://trial.medpath.com/news/praxis-precision-medicines-provides-corporate-update-and-globenewswire 2024-11-06T12:34:12+00:00 weekly 0.7 https://trial.medpath.com/news/caris-life-sciences-receives-fda-approval-for-mi-cancer-seektm-as-a-companion 2024-11-06T12:33:00+00:00 weekly 0.7 https://trial.medpath.com/news/ionis-reports-third-quarter-2024-financial-results-morningstar 2024-11-06T12:32:59+00:00 weekly 0.7 https://trial.medpath.com/news/ionis-reports-third-quarter-2024-financial-results-stock-titan 2024-11-06T12:19:06+00:00 weekly 0.7 https://trial.medpath.com/news/dupixent-r-dupilumab-approved-in-the-european-union-as-the-first-and-only-medicine-for 2024-11-06T12:13:38+00:00 weekly 0.7 https://trial.medpath.com/news/ionis-reports-third-quarter-2024-financial-results-placera 2024-11-06T12:10:07+00:00 weekly 0.7 https://trial.medpath.com/news/insignis-therapeutics-in-001-clinical-programme-receives-positive-fda-response 2024-11-06T12:08:59+00:00 weekly 0.7 https://trial.medpath.com/news/lenz-therapeutics-reports-third-quarter-2024-financial-results-morningstar 2024-11-06T12:08:58+00:00 weekly 0.7 https://trial.medpath.com/news/chinese-herbal-medicine-may-aid-dementia-prevention-mirage-news 2024-11-06T12:05:15+00:00 weekly 0.7 https://trial.medpath.com/news/ionis-announces-pivotal-phase-3-trial-design-for-ion582-in-angelman-syndrome 2024-11-06T12:04:14+00:00 weekly 0.7 https://trial.medpath.com/news/ionis-reports-third-quarter-2024-financial-results-pr-newswire 2024-11-06T12:04:13+00:00 weekly 0.7 https://trial.medpath.com/news/imugene-bile-cancer-patient-maintains-full-response-mirage-news 2024-11-06T11:43:54+00:00 weekly 0.7 https://trial.medpath.com/news/caris-life-sciences-receives-fda-approval-for-mi-cancer-seektm-as-a-companion 2024-11-06T11:36:05+00:00 weekly 0.7 https://trial.medpath.com/news/mhra-grants-approval-for-bladder-cancer-drug-erdafitinib-pharmatimes 2024-11-06T11:08:32+00:00 weekly 0.7 https://trial.medpath.com/news/italy-tests-first-gene-edited-vines-for-winemaking-nature-biotechnology 2024-11-06T11:07:30+00:00 weekly 0.7 https://trial.medpath.com/news/new-trial-seeks-to-improve-ewing-sarcoma-treatment-outcomes-technology-networks 2024-11-06T11:02:17+00:00 weekly 0.7 https://trial.medpath.com/news/gender-gap-persists-in-hematology-oncology-leadership-despite-growing-female-representation-in-medicine 2024-11-06T11:00:36+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-signs-deal-for-monthly-glp-1-agonist-european-biotechnology-magazine 2024-11-06T10:42:53+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-first-crispr-cas13-rna-editing-trial-for-macular-degeneration 2024-11-06T10:39:08+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-dupixent-approved-in-the-eu-as-the-first-and-only-medicine-for-young 2024-11-06T10:30:13+00:00 weekly 0.7 https://trial.medpath.com/news/capsida-biotherapeutics-cap-003-displays-properties-of-disease-modification-in-cgtlive-r 2024-11-06T10:17:18+00:00 weekly 0.7 https://trial.medpath.com/news/lumateperone-demonstrates-efficacy-in-reducing-symptomatic-relapse-risk-in-schizophrenia 2024-11-06T10:16:39+00:00 weekly 0.7 https://trial.medpath.com/news/minghui-pharmaceutical-announces-promising-initial-results-from-phase-i-clinical-trial-of 2024-11-06T10:04:14+00:00 weekly 0.7 https://trial.medpath.com/news/eu-s-new-wastewater-treatment-directive-raises-concerns-over-generic-medicine-access 2024-11-06T10:03:06+00:00 weekly 0.7 https://trial.medpath.com/news/insignis-therapeutics-receives-positive-fda-feedback-on-in-001-clinical-program-for 2024-11-06T09:14:59+00:00 weekly 0.7 https://trial.medpath.com/news/antengene-to-present-results-from-two-late-stage-studies-of-selinexor-signaling-potential 2024-11-06T09:14:58+00:00 weekly 0.7 https://trial.medpath.com/news/syndax-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-06T09:14:57+00:00 weekly 0.7 https://trial.medpath.com/news/lyell-announces-presentation-of-initial-clinical-data-from-the-phase-1-2-clinical-trial-of-biospace 2024-11-06T09:14:55+00:00 weekly 0.7 https://trial.medpath.com/news/fda-roundup-november-5-2024-biospace 2024-11-06T09:14:54+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-announces-late-breaking-abstract-of-thio-101-updates-selected-biospace 2024-11-06T09:14:52+00:00 weekly 0.7 https://trial.medpath.com/news/update-on-fda-review-of-vtama-r-tapinarof-cream-1-for-the-treatment-of-atopic-biospace 2024-11-06T09:14:51+00:00 weekly 0.7 https://trial.medpath.com/news/protagonist-therapeutics-announces-poster-presentation-on-final-revive-phase-2-study 2024-11-06T09:14:48+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-s-rsv-vaccine-approved-in-canada-for-adults-aged-50-to-59 2024-11-06T09:05:09+00:00 weekly 0.7 https://trial.medpath.com/news/vesper-bio-announces-successful-completion-of-phase-1-clinical-trial-for-ftd-grn-treatment 2024-11-06T09:00:15+00:00 weekly 0.7 https://trial.medpath.com/news/jlk-receives-fda-approval-for-its-ai-stroke-diagnosis-solution-jlk-pwi-businesskorea 2024-11-06T08:55:54+00:00 weekly 0.7 https://trial.medpath.com/news/dr-lotan-on-ongoing-research-with-novel-agents-in-bcg-unresponsive-nmibc-onclive 2024-11-06T08:47:10+00:00 weekly 0.7 https://trial.medpath.com/news/ruxolitinib-plus-pegylated-interferon-alfa-2a-is-safe-and-effective-in-in-newly-diagnosed-pv 2024-11-06T08:46:45+00:00 weekly 0.7 https://trial.medpath.com/news/in-depth-analysis-showing-robust-diamyd-r-treatment-effects-across-clinical-trials-to-morningstar 2024-11-06T08:36:19+00:00 weekly 0.7 https://trial.medpath.com/news/in-depth-analysis-showing-robust-diamyd-r-treatment-effects-across-clinical-trials-to-be 2024-11-06T08:13:26+00:00 weekly 0.7 https://trial.medpath.com/news/noninflammatory-neurotoxicity-events-in-patients-receiving-car-t-cgtlive-r 2024-11-06T07:06:55+00:00 weekly 0.7 https://trial.medpath.com/news/patient-death-reported-in-beam-scd-phase-i-ii-study-bioworld 2024-11-06T06:51:11+00:00 weekly 0.7 https://trial.medpath.com/news/igi-reports-75-response-rate-in-multiple-myeloma-drug-trial-the-hindu-businessline 2024-11-06T06:47:16+00:00 weekly 0.7 https://trial.medpath.com/news/dupixent-r-dupilumab-approved-in-the-european-union-as-the-first-and-only-medicine-for 2024-11-06T06:45:14+00:00 weekly 0.7 https://trial.medpath.com/news/ultimovacs-asa-reports-third-quarter-2024-financial-results-globenewswire 2024-11-06T06:43:29+00:00 weekly 0.7 https://trial.medpath.com/news/antengene-to-present-results-from-two-late-stage-studies-of-selinexor-signaling-potential 2024-11-06T06:34:37+00:00 weekly 0.7 https://trial.medpath.com/news/korean-aml-drug-shows-50-overall-complete-response-rate-in-p1-trial-kbr 2024-11-06T06:28:08+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-dupixent-approved-in-the-eu-as-the-first-and-globenewswire 2024-11-06T06:09:19+00:00 weekly 0.7 https://trial.medpath.com/news/final-rounds-of-late-breaking-clinical-trial-results-announced-at-viva24-pr-newswire 2024-11-06T05:58:47+00:00 weekly 0.7 https://trial.medpath.com/news/final-rounds-of-late-breaking-clinical-trial-results-announced-at-viva24-yahoo-finance 2024-11-06T05:25:22+00:00 weekly 0.7 https://trial.medpath.com/news/rosacea-clinical-trials-2024-ema-pdma-fda-approvals-openpr-com 2024-11-06T04:43:07+00:00 weekly 0.7 https://trial.medpath.com/news/bostongene-advances-precision-oncology-with-ai-driven-molecular-profiling-research-at-major-cancer-symposiums 2024-11-06T04:34:35+00:00 weekly 0.7 https://trial.medpath.com/news/hutchmed-highlights-clinical-data-to-be-presented-at-the-globenewswire 2024-11-06T04:09:01+00:00 weekly 0.7 https://trial.medpath.com/news/cstone-pharmaceuticals-to-unveil-promising-lymphoma-drug-data-markets-insider 2024-11-06T03:55:37+00:00 weekly 0.7 https://trial.medpath.com/news/acadia-pharmaceuticals-secures-150m-in-priority-review-voucher-sale-setting-high-benchmark 2024-11-06T03:35:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-to-help-patients-undergoing-cancer-immunotherapy-yale-school-of-medicine 2024-11-06T03:24:05+00:00 weekly 0.7 https://trial.medpath.com/news/fda-pushes-back-pdufa-date-3-months-for-tapinarof-1-cream-for-atopic-dermatitis-in 2024-11-06T02:54:49+00:00 weekly 0.7 https://trial.medpath.com/news/fda-delays-decision-on-merus-bispecific-antibody-to-review-cmc-information-biospace 2024-11-06T02:36:10+00:00 weekly 0.7 https://trial.medpath.com/news/research-grid-secures-6-5m-seed-funding-to-revolutionize-clinical-trial-efficiency-with-ai 2024-11-06T01:52:11+00:00 weekly 0.7 https://trial.medpath.com/news/antengene-to-present-results-from-two-late-stage-studies-of-selinexor-signaling-potential 2024-11-06T00:50:11+00:00 weekly 0.7 https://trial.medpath.com/news/antengene-to-present-results-from-two-late-stage-studies-of-selinexor-signaling-potential 2024-11-06T00:33:11+00:00 weekly 0.7 https://trial.medpath.com/news/nanoscope-therapeutics-retinitis-pigmentosa-gene-therapy-mco-010-improves-visual 2024-11-06T00:16:57+00:00 weekly 0.7 https://trial.medpath.com/news/leads-biolabs-receives-orphan-drug-designation-from-the-us-fda-for-lbl-034-a-uniquely-designed-highly-differentiated-anti-gprc5d-cd3-bispecific-antibody-for-the-treatment-of-multiple-myeloma 2024-11-06T00:11:07+00:00 weekly 0.7 https://trial.medpath.com/news/how-hypoxia-helps-cancer-spread-johns-hopkins-medicine 2024-11-06T00:01:53+00:00 weekly 0.7 https://trial.medpath.com/news/pp-007-receives-fda-fast-track-designation-for-treatment-of-acute-ischemic-stroke 2024-11-05T23:59:12+00:00 weekly 0.7 https://trial.medpath.com/news/implementation-of-the-new-european-health-technology-assessment-regulation-htar 2024-11-05T23:57:45+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-journey-s-rosacea-drug-eu-to-decide-on-novo-s-catalent-acquisition-by-6-december 2024-11-05T23:44:31+00:00 weekly 0.7 https://trial.medpath.com/news/puma-biotechnology-launches-phase-ii-trial-of-alisertib-for-hr-positive-metastatic-breast-cancer 2024-11-05T23:01:52+00:00 weekly 0.7 https://trial.medpath.com/news/new-swiss-clinical-trial-framework-takes-effect-with-updated-reporting-rules-citeline 2024-11-05T22:59:56+00:00 weekly 0.7 https://trial.medpath.com/news/quoin-pharmaceuticals-initiates-clinical-testing-of-lead-product-in-pediatric-netherton 2024-11-05T22:06:39+00:00 weekly 0.7 https://trial.medpath.com/news/anaptysbio-inc-sec-10-q-report-tradingview 2024-11-05T22:03:58+00:00 weekly 0.7 https://trial.medpath.com/news/stoke-therapeutics-inc-sec-10-q-report-tradingview 2024-11-05T22:03:58+00:00 weekly 0.7 https://trial.medpath.com/news/an-orally-bioavailable-gcn2-kinase-activator-for-the-treatment-of-clear-cell-renal-cell-carcinoma-and-acute-myeloid-leukemia 2024-11-05T21:53:39+00:00 weekly 0.7 https://trial.medpath.com/news/new-drug-combo-shows-significant-promise-in-advanced-melanoma-trial 2024-11-05T21:41:47+00:00 weekly 0.7 https://trial.medpath.com/news/humacyte-s-atev-promising-clinical-performance-and-market-potential-drive-buy-rating 2024-11-05T21:25:41+00:00 weekly 0.7 https://trial.medpath.com/news/anaptys-announces-third-quarter-2024-financial-results-and-provides-business-update 2024-11-05T21:18:07+00:00 weekly 0.7 https://trial.medpath.com/news/poseida-to-unveil-breakthrough-cancer-therapy-data-at-sitc-ash-2024-conferences 2024-11-05T21:10:25+00:00 weekly 0.7 https://trial.medpath.com/news/syndax-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-05T21:08:17+00:00 weekly 0.7 https://trial.medpath.com/news/ultragenyx-reports-third-quarter-2024-financial-results-and-corporate-update 2024-11-05T21:05:55+00:00 weekly 0.7 https://trial.medpath.com/news/fda-pushes-zenocutuzumab-decision-date-in-ngr1-nsclc-pdac-targeted-oncology 2024-11-05T20:49:42+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-de-novo-authorization-to-photobiomodulation-device-for-dry-amd-healio 2024-11-05T20:44:47+00:00 weekly 0.7 https://trial.medpath.com/news/kite-to-highlight-industry-leading-car-t-cell-therapy-portfolio-at-ash-2024-including 2024-11-05T20:30:41+00:00 weekly 0.7 https://trial.medpath.com/news/highlights-in-prostate-cancer-treatment-advances-from-esmo-2024-ursula-vogl 2024-11-05T20:20:38+00:00 weekly 0.7 https://trial.medpath.com/news/highlights-in-prostate-cancer-treatment-advances-from-esmo-2024-ursula-vogl 2024-11-05T20:16:49+00:00 weekly 0.7 https://trial.medpath.com/news/amc-health-receives-expanded-fda-clearance-for-advanced-virtual-care-and-risk 2024-11-05T20:03:30+00:00 weekly 0.7 https://trial.medpath.com/news/vertex-stock-flashes-a-surprise-entry-as-non-opioid-pain-drug-looms-investor-s-business-daily 2024-11-05T19:40:02+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-novel-combination-regimen-for-gi-cancers-the-asco-post 2024-11-05T19:38:30+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-drug-shows-slower-cognitive-decline-in-lower-tau-patients 2024-11-05T19:38:26+00:00 weekly 0.7 https://trial.medpath.com/news/genentech-to-present-blood-disorders-data-at-ash-markets-insider 2024-11-05T19:35:55+00:00 weekly 0.7 https://trial.medpath.com/news/ash24-novo-nordisk-takes-forma-s-sickle-cell-treatment-into-phase-3-endpoints-news 2024-11-05T19:33:09+00:00 weekly 0.7 https://trial.medpath.com/news/genomic-variations-associated-with-risk-and-protection-against-vincristine-induced-nature 2024-11-05T19:31:29+00:00 weekly 0.7 https://trial.medpath.com/news/organon-fda-extends-vtama-atopic-dermatitis-review-to-march-morningstar 2024-11-05T19:25:27+00:00 weekly 0.7 https://trial.medpath.com/news/quoin-pharmaceuticals-initiates-clinical-testing-of-lead-product-in-pediatric-netherton 2024-11-05T19:13:41+00:00 weekly 0.7 https://trial.medpath.com/news/organon-co-filed-sec-form-8-k-regulation-fd-disclosure-financial-statements-and-exhibits 2024-11-05T18:58:49+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-envoy-medical-s-study-for-fully-implanted-cochlear-implant 2024-11-05T18:57:17+00:00 weekly 0.7 https://trial.medpath.com/news/st-luke-s-surgeon-recognized-among-top-cited-scientists-saucon-source 2024-11-05T18:49:02+00:00 weekly 0.7 https://trial.medpath.com/news/journey-medical-s-emrosi-secures-fda-nod-for-rosacea-treatment 2024-11-05T18:37:27+00:00 weekly 0.7 https://trial.medpath.com/news/amc-health-receives-expanded-fda-clearance-for-advanced-virtual-care-and-risk 2024-11-05T18:27:55+00:00 weekly 0.7 https://trial.medpath.com/news/a-trial-of-vistusertib-and-paclitaxel-for-ovarian-cancer-that-has-come-back-octopus 2024-11-05T18:21:23+00:00 weekly 0.7 https://trial.medpath.com/news/sickle-cell-patient-dies-in-beam-study-of-base-editing-therapy-biopharma-dive 2024-11-05T18:13:05+00:00 weekly 0.7 https://trial.medpath.com/news/new-momentum-for-a-time-limited-conditional-approval-pathway-for-rare-disease-drugs 2024-11-05T18:12:55+00:00 weekly 0.7 https://trial.medpath.com/news/case-study-shows-striking-improvements-in-patient-with-metastatic-prostate-cancer 2024-11-05T18:11:07+00:00 weekly 0.7 https://trial.medpath.com/news/phase-1-2-trial-of-del-brax-enrolling-new-possibly-pivotal-fshd-group-muscular-dystrophy-news 2024-11-05T18:09:04+00:00 weekly 0.7 https://trial.medpath.com/news/medtronic-recor-medical-score-renal-denervation-reimbursement-wins-massdevice 2024-11-05T18:07:37+00:00 weekly 0.7 https://trial.medpath.com/news/medtronic-recor-win-cms-transitional-payment-coverage-for-renal-denervation-devices 2024-11-05T17:50:01+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-journey-medical-s-emrosi-for-rosacea-drug-topics 2024-11-05T17:31:27+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-ablas-for-prolia-r-xgeva-r-biosimilars-from-organon-and-teva-venable-llp 2024-11-05T17:22:58+00:00 weekly 0.7 https://trial.medpath.com/news/iterum-therapeutics-receives-fda-ok-for-orlynvah-drug-store-news 2024-11-05T17:19:27+00:00 weekly 0.7 https://trial.medpath.com/news/ribomic-announces-positive-interim-results-from-phase-iia-trial-of-umedaptanib-pegol-in 2024-11-05T17:18:46+00:00 weekly 0.7 https://trial.medpath.com/news/sigmar1-activating-agent-blarcamesine-meets-pre-specified-efficacy-in-phase-2-3-trial-of 2024-11-05T17:11:40+00:00 weekly 0.7 https://trial.medpath.com/news/fda-extends-review-period-for-zenocutuzumab-in-nrg1-pdac-nsclc 2024-11-05T17:07:16+00:00 weekly 0.7 https://trial.medpath.com/news/dr-haggstrom-on-future-research-directions-in-egfr-and-alk-nsclc-onclive 2024-11-05T17:02:51+00:00 weekly 0.7 https://trial.medpath.com/news/lucky-gene-therapy-break-for-daily-wage-earner-s-son-times-of-india 2024-11-05T17:01:05+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-to-help-patients-undergoing-cancer-immunotherapy-yale-school-of-medicine 2024-11-05T16:57:28+00:00 weekly 0.7 https://trial.medpath.com/news/bolt-medical-announces-completion-of-restore-atk-and-restore-btk-pivotal-studies 2024-11-05T16:41:09+00:00 weekly 0.7 https://trial.medpath.com/news/h-c-wainwright-rytelo-off-to-a-strong-launch-assigns-buy-to-geron-shares-investing-com 2024-11-05T16:31:58+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-announces-positive-results-from-phase-3-essence-trial-of-semaglutide-2-4 2024-11-05T16:31:02+00:00 weekly 0.7 https://trial.medpath.com/news/damona-pharmaceuticals-given-fda-approval-for-trial-of-dpx-101-for-brain-disorders 2024-11-05T16:26:39+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-announces-late-breaking-abstract-of-thio-101-updates-selected-for 2024-11-05T16:25:43+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-journey-medical-s-rosacea-treatment-emrosi-pharmaceutical-technology 2024-11-05T16:20:54+00:00 weekly 0.7 https://trial.medpath.com/news/diamyd-medical-and-innodia-partner-for-type-1-diabetes-awareness-and-patient-cision-news 2024-11-05T16:09:21+00:00 weekly 0.7 https://trial.medpath.com/news/diamyd-medical-and-innodia-partner-for-type-1-diabetes-awareness-and-patient 2024-11-05T16:05:35+00:00 weekly 0.7 https://trial.medpath.com/news/diamyd-medical-and-innodia-partner-for-type-1-diabetes-awareness-and-patient-placera 2024-11-05T16:04:52+00:00 weekly 0.7 https://trial.medpath.com/news/lyell-announces-presentation-of-initial-clinical-data-from-globenewswire 2024-11-05T15:49:57+00:00 weekly 0.7 https://trial.medpath.com/news/brief-overview-of-perseus-iskia-and-cassiopeia-clinical-trials-cancer-network 2024-11-05T15:34:37+00:00 weekly 0.7 https://trial.medpath.com/news/native-hawaiians-pacific-islanders-found-to-be-underrepresented-in-clinical-trials 2024-11-05T15:34:17+00:00 weekly 0.7 https://trial.medpath.com/news/trials-update-our-q3-roundup-of-dementia-clinical-trials-news-being-patient 2024-11-05T15:29:14+00:00 weekly 0.7 https://trial.medpath.com/news/drap-launches-industry-e-reporting-system-to-monitor-drug-reaction-dental-news 2024-11-05T15:26:35+00:00 weekly 0.7 https://trial.medpath.com/news/pioneering-clinical-trial-to-treat-cancer-in-patients-with-fanconi-anaemia-uab 2024-11-05T15:23:41+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-announces-late-breaking-abstract-of-thio-101-updates-markets-data 2024-11-05T15:07:07+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-announces-late-breaking-abstract-of-thio-101-updates-selected-for 2024-11-05T15:05:50+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-announces-late-breaking-abstract-of-thio-101-updates-selected-for 2024-11-05T14:58:39+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-dfd-29-for-treatment-of-adults-with-rosacea-related-inflammatory-lesions 2024-11-05T14:52:01+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-announces-late-breaking-abstract-of-thio-101-updates-selected-for 2024-11-05T14:51:58+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-announces-late-breaking-abstract-of-thio-101-updates-selected-placera 2024-11-05T14:49:41+00:00 weekly 0.7 https://trial.medpath.com/news/fda-extends-pdufa-date-for-zenocutuzumab-in-nrg1-nsclc-and-pancreatic-cancer 2024-11-05T14:47:26+00:00 weekly 0.7 https://trial.medpath.com/news/lyell-announces-presentation-of-initial-clinical-data-from-the-phase-1-2-clinical-trial-of 2024-11-05T14:46:36+00:00 weekly 0.7 https://trial.medpath.com/news/encouraging-data-revealed-for-schizophrenia-long-acting-injectables 2024-11-05T14:27:39+00:00 weekly 0.7 https://trial.medpath.com/news/roche-to-present-new-and-encouraging-long-term-follow-up-globenewswire 2024-11-05T14:26:28+00:00 weekly 0.7 https://trial.medpath.com/news/genentech-to-present-new-and-encouraging-long-term-follow-up-data-across-morningstar 2024-11-05T14:23:55+00:00 weekly 0.7 https://trial.medpath.com/news/ark-clinical-research-s-new-mobile-unit-pioneering-decentralized-clinical-morningstar 2024-11-05T14:23:50+00:00 weekly 0.7 https://trial.medpath.com/news/genentech-to-present-new-and-encouraging-long-term-follow-up-data-across-broad 2024-11-05T14:23:10+00:00 weekly 0.7 https://trial.medpath.com/news/nurix-to-present-breakthrough-btk-degrader-data-at-ash-clinical-trial-results-revealed 2024-11-05T14:20:06+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-to-present-breakthrough-phase-3-results-for-jaypirca-at-ash-annual-meeting 2024-11-05T14:10:24+00:00 weekly 0.7 https://trial.medpath.com/news/onclive-s-october-roundup-of-key-fda-approvals-in-oncology 2024-11-05T14:08:56+00:00 weekly 0.7 https://trial.medpath.com/news/ark-clinical-research-s-new-mobile-unit-pioneering-decentralized-clinical-yahoo-finance 2024-11-05T14:06:02+00:00 weekly 0.7 https://trial.medpath.com/news/nuvectis-pharma-inc-sec-10-q-report-tradingview 2024-11-05T14:03:25+00:00 weekly 0.7 https://trial.medpath.com/news/karyopharm-reports-third-quarter-2024-financial-results-and-highlights-recent-company-progress 2024-11-05T13:56:48+00:00 weekly 0.7 https://trial.medpath.com/news/a-potent-intramolecular-nlrp3-glue-inhibitor-advancing-through-multiple-phase-ii-trials 2024-11-05T13:43:11+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-s-fasenra-approved-by-ec-to-treat-rare-inflammatory-disease-egpa-pmlive 2024-11-05T13:37:35+00:00 weekly 0.7 https://trial.medpath.com/news/ema-accepts-marketing-authorization-application-for-biosimilar-to-simponi 2024-11-05T13:31:29+00:00 weekly 0.7 https://trial.medpath.com/news/quoin-pharmaceuticals-initiates-clinical-testing-of-lead-product-in-pediatric-netherton 2024-11-05T13:17:46+00:00 weekly 0.7 https://trial.medpath.com/news/imugene-says-bile-tract-cancer-patient-maintains-complete-response-in-mast-study-biotech 2024-11-05T13:13:56+00:00 weekly 0.7 https://trial.medpath.com/news/quoin-pharmaceuticals-initiates-clinical-testing-of-lead-globenewswire 2024-11-05T13:13:44+00:00 weekly 0.7 https://trial.medpath.com/news/ankyra-therapeutics-announces-first-visceral-tumor-patient-dosed-in-phase-1-anchor 2024-11-05T13:09:32+00:00 weekly 0.7 https://trial.medpath.com/news/insignis-therapeutics-receives-positive-fda-feedback-on-in-001-clinical-program-for 2024-11-05T13:09:30+00:00 weekly 0.7 https://trial.medpath.com/news/quoin-s-qrx003-shows-promise-in-pediatric-netherton-syndrome-trial-expansion-stock-titan 2024-11-05T13:05:30+00:00 weekly 0.7 https://trial.medpath.com/news/new-coalition-launches-to-transform-cancer-supportive-care-delivery-nationwide 2024-11-05T13:00:35+00:00 weekly 0.7 https://trial.medpath.com/news/ema-accepts-alvotech-and-advanz-pharma-s-avt05-maa-yahoo-finance 2024-11-05T12:40:39+00:00 weekly 0.7 https://trial.medpath.com/news/phaxiam-therapeutics-receives-fda-clearance-to-initiate-phase-ii-gloria-study-in-the-u-s 2024-11-05T12:39:42+00:00 weekly 0.7 https://trial.medpath.com/news/intra-cellular-therapies-announces-positive-topline-results-in-phase-3-trial-evaluating 2024-11-05T12:37:24+00:00 weekly 0.7 https://trial.medpath.com/news/ac-immune-reports-third-quarter-2024-financial-results-and-provides-a-corporate-update 2024-11-05T12:37:22+00:00 weekly 0.7 https://trial.medpath.com/news/delta-fly-pharma-inc-update-for-expanded-phase-i-study-of-dfp-14927-afp-com 2024-11-05T12:34:47+00:00 weekly 0.7 https://trial.medpath.com/news/zyversa-s-breakthrough-new-data-shows-promise-for-type-2-diabetes-prevention-zvsa-stock 2024-11-05T12:33:09+00:00 weekly 0.7 https://trial.medpath.com/news/zymeworks-announces-first-patient-dosed-in-phase-1-clinical-trial-evaluating-zw191-biospace 2024-11-05T12:21:16+00:00 weekly 0.7 https://trial.medpath.com/news/philips-enrolls-first-patient-in-u-s-clinical-trial-for-innovative-integrated-single-device-to-treat 2024-11-05T12:21:16+00:00 weekly 0.7 https://trial.medpath.com/news/angitia-biopharmaceuticals-announces-dosing-of-first-patient-in-phase-2-clinical-trial-of 2024-11-05T12:21:05+00:00 weekly 0.7 https://trial.medpath.com/news/national-hiv-drug-resistance-surveillance-among-adults-with-viral-non-suppression-in-south-africa 2024-11-05T12:21:00+00:00 weekly 0.7 https://trial.medpath.com/news/germany-announces-2-further-planned-adult-use-cannabis-trials-but-legislation-not-yet 2024-11-05T12:18:24+00:00 weekly 0.7 https://trial.medpath.com/news/ema-accepts-alvotech-and-advanz-pharma-s-avt05-maa-pharmaceutical-technology 2024-11-05T12:14:54+00:00 weekly 0.7 https://trial.medpath.com/news/itci-s-caplyta-shows-breakthrough-63-reduction-in-schizophrenia-relapse-risk 2024-11-05T12:13:51+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-bolsters-obesity-pipeline-with-promising-early-data-for-candidates-biospace 2024-11-05T12:12:45+00:00 weekly 0.7 https://trial.medpath.com/news/s93-phase-3-notus-trial-dupilumab-efficacy-and-safety-in-patients-with-moderate-to-severe 2024-11-05T11:58:34+00:00 weekly 0.7 https://trial.medpath.com/news/how-3d-printing-could-transform-solid-oral-dosage-forms-the-medicine-maker 2024-11-05T11:34:27+00:00 weekly 0.7 https://trial.medpath.com/news/how-hybrid-models-and-tech-are-shaping-the-future-of-clinical-research 2024-11-05T11:29:34+00:00 weekly 0.7 https://trial.medpath.com/news/how-this-clinical-trial-could-help-alzheimer-s-patients-wptv 2024-11-05T11:20:46+00:00 weekly 0.7 https://trial.medpath.com/news/zymeworks-announces-first-patient-dosed-in-phase-1-clinical-trial-evaluating-zw191-in 2024-11-05T11:12:58+00:00 weekly 0.7 https://trial.medpath.com/news/why-treatments-can-fail-folks-with-wet-macular-degeneration-and-what-might-really-work 2024-11-05T11:11:26+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-service-vertex-reports-third-quarter-2024-financial-results 2024-11-05T11:03:49+00:00 weekly 0.7 https://trial.medpath.com/news/the-reliever-reliance-test-evaluating-a-new-tool-to-address-saba-over-reliance-nature 2024-11-05T10:58:47+00:00 weekly 0.7 https://trial.medpath.com/news/interleukin-6-receptor-antibodies-tocilizumab-in-acute-myocardial-infarction-with-trials 2024-11-05T10:45:57+00:00 weekly 0.7 https://trial.medpath.com/news/northwest-ehealth-nweh-announces-a-pilot-to-test-a-new-model-for-finding-and-recruiting 2024-11-05T10:29:09+00:00 weekly 0.7 https://trial.medpath.com/news/how-this-clinical-trial-could-help-alzheimer-s-patients-wflx 2024-11-05T10:18:30+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-prenatal-therapy-saves-children-with-congenital-vascular-malformations 2024-11-05T10:13:33+00:00 weekly 0.7 https://trial.medpath.com/news/neuropace-announces-fda-submission-of-three-year-data-from-post-approval-study-of 2024-11-05T10:07:17+00:00 weekly 0.7 https://trial.medpath.com/news/leading-cancer-centers-form-ai-alliance-with-40m-tech-industry-backing-to-revolutionize-cancer-research 2024-11-05T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/alvotech-and-teva-announce-fda-approval-of-additional-presentation-for-ustekinumab-biosimilar 2024-11-05T09:56:49+00:00 weekly 0.7 https://trial.medpath.com/news/janus-kinase-jak-inhibitors-pipeline-assessment-2024-ema-openpr-com 2024-11-05T09:54:23+00:00 weekly 0.7 https://trial.medpath.com/news/photocure-partner-asieris-announces-marketing-approval-by-the-national-medical-products 2024-11-05T09:44:58+00:00 weekly 0.7 https://trial.medpath.com/news/qyuns-therapeutics-drug-approval-boosts-market-presence-tipranks-com 2024-11-05T09:43:18+00:00 weekly 0.7 https://trial.medpath.com/news/european-medicines-agency-confirms-acceptance-of-marketing-authorization-pipelinereview 2024-11-05T09:13:04+00:00 weekly 0.7 https://trial.medpath.com/news/november-5-2024-study-snapshot-and-updated-ethics-documentation-available-for-moms 2024-11-05T09:05:33+00:00 weekly 0.7 https://trial.medpath.com/news/eligibility-and-endpoints-for-clinical-trials-in-trimodality-therapy-for-bladder-cancer 2024-11-05T09:02:12+00:00 weekly 0.7 https://trial.medpath.com/news/oak-hill-bio-and-chiesi-s-ohb-607-trial-enrols-first-european-subject-for-bpd-prevention 2024-11-05T09:00:35+00:00 weekly 0.7 https://trial.medpath.com/news/who-launches-new-clinical-trials-guidance-what-do-i-need-to-know 2024-11-05T08:51:31+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-and-safety-of-jmt103-in-patients-with-unresectable-or-surgically-challenging-giant-nature 2024-11-05T07:38:52+00:00 weekly 0.7 https://trial.medpath.com/news/european-medicines-agency-confirms-acceptance-of-marketing-authorization-application 2024-11-05T07:21:37+00:00 weekly 0.7 https://trial.medpath.com/news/abbott-s-freestyle-libre-cgm-systems-receive-first-ever-approval-for-use-during-medical-imaging-as-semaglutide-supply-stabilizes 2024-11-05T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/hookipa-pharma-s-swot-analysis-stock-s-potential-in-immunotherapy-market 2024-11-05T06:41:57+00:00 weekly 0.7 https://trial.medpath.com/news/uk-government-partners-with-oxford-nanopore-to-launch-nhs-wide-pathogen-surveillance-system 2024-11-05T06:20:04+00:00 weekly 0.7 https://trial.medpath.com/news/medical-moment-new-fda-approved-implants-for-shoulder-replacements-wndu 2024-11-05T06:15:40+00:00 weekly 0.7 https://trial.medpath.com/news/pembrolizumab-combo-shows-promising-results-in-high-risk-cervical-cancer 2024-11-05T06:01:47+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-gap-in-masld-related-liver-cancer-screening-26-of-non-cirrhotic-cases-show-low-fib-4-scores 2024-11-05T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-rounds-of-late-breaking-clinical-trial-results-announced-at-viva24-yahoo-finance 2024-11-05T05:56:14+00:00 weekly 0.7 https://trial.medpath.com/news/first-rounds-of-late-breaking-clinical-trial-results-announced-at-viva24-pr-newswire 2024-11-05T05:51:42+00:00 weekly 0.7 https://trial.medpath.com/news/ncats-award-will-support-multi-site-study-to-evaluate-remote-trials-university-at-buffalo 2024-11-05T05:42:07+00:00 weekly 0.7 https://trial.medpath.com/news/biocity-presents-late-breaking-clinical-trial-results-with-sc0062-for-iga-nephropathy-at-asn 2024-11-05T05:40:18+00:00 weekly 0.7 https://trial.medpath.com/news/northwest-ehealth-nweh-announces-a-pilot-to-test-a-new-model-for-finding-and-recruiting 2024-11-05T05:14:32+00:00 weekly 0.7 https://trial.medpath.com/news/iron-chelator-deferiprone-shows-adverse-effects-in-early-alzheimer-s-disease-trial 2024-11-05T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/world-s-first-drug-to-regrow-teeth-is-now-in-clinical-trials-the-brighter-side-of-news 2024-11-05T04:48:41+00:00 weekly 0.7 https://trial.medpath.com/news/lumithera-obtains-fda-authorization-of-valeda-treatment-for-dry-amd-patients-to-improve-vision 2024-11-05T04:35:01+00:00 weekly 0.7 https://trial.medpath.com/news/verona-pharma-reports-strong-q3-launch-for-copd-drug-tipranks-com 2024-11-05T04:20:48+00:00 weekly 0.7 https://trial.medpath.com/news/cytodyn-inc-announces-fda-clearance-of-its-phase-ii-oncology-trial-marketscreener 2024-11-05T03:26:48+00:00 weekly 0.7 https://trial.medpath.com/news/ribomic-announces-positive-interim-results-from-phase-iia-trial-of-umedaptanib-pegol-in-achondroplasia 2024-11-05T03:11:38+00:00 weekly 0.7 https://trial.medpath.com/news/vertex-pharmaceuticals-vrtx-q3-2024-earnings-call-transcript-the-globe-and-mail 2024-11-05T02:42:03+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-or-bust-big-pharma-s-surprising-moves-jomfruland-net 2024-11-05T02:34:54+00:00 weekly 0.7 https://trial.medpath.com/news/xencor-doses-first-subject-in-phase-1-2-study-of-xmab-r-942-in-development-for-patients 2024-11-05T02:14:45+00:00 weekly 0.7 https://trial.medpath.com/news/sana-biotechnology-pivots-to-autoimmune-focus-announces-layoffs-and-pipeline-restructuring 2024-11-05T01:40:00+00:00 weekly 0.7 https://trial.medpath.com/news/recce-says-patient-dosing-in-phase-2-clinical-trial-advances-to-final-stages-biotech 2024-11-05T01:34:01+00:00 weekly 0.7 https://trial.medpath.com/news/cervomed-announces-key-takeaways-from-oral-presentations-at-the-17th-clinical-trials-on 2024-11-05T01:26:31+00:00 weekly 0.7 https://trial.medpath.com/news/niagara-trial-shows-durvalumab-plus-chemotherapy-improves-survival-in-muscle 2024-11-05T01:26:12+00:00 weekly 0.7 https://trial.medpath.com/news/nationwide-epilepsy-clinical-trial-investigates-potential-new-treatment-the-rochelle-news-leader 2024-11-05T01:13:45+00:00 weekly 0.7 https://trial.medpath.com/news/merus-receives-fda-extension-of-pdufa-for-zenocutuzumab 2024-11-05T01:11:36+00:00 weekly 0.7 https://trial.medpath.com/news/quantatm-dialysis-system-receives-fda-clearance-for-home-hemodialysis 2024-11-05T00:52:34+00:00 weekly 0.7 https://trial.medpath.com/news/5-year-follow-up-of-the-phase-2-optic-study-in-patients-with-chronic-phase-chronic-myeloid-leukemia 2024-11-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-type-1-diabetes-reprogramming-fat-cells-to-restore-insulin-production 2024-11-04T23:59:55+00:00 weekly 0.7 https://trial.medpath.com/news/guess-which-asx-300-stock-is-jumping-11-on-big-news-motley-fool 2024-11-04T23:32:22+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ide-for-akura-medical-s-thrombectomy-system-massdevice 2024-11-04T23:28:19+00:00 weekly 0.7 https://trial.medpath.com/news/neuraxis-wins-expanded-fda-clearance-for-non-implanted-neurostim-for-pain-relief 2024-11-04T23:28:19+00:00 weekly 0.7 https://trial.medpath.com/news/teva-shares-positive-phase-iii-data-of-schizophrenia-injectable-tev-749 2024-11-04T23:23:49+00:00 weekly 0.7 https://trial.medpath.com/news/unity-biotechnology-inc-sec-10-q-report-tradingview 2024-11-04T23:16:21+00:00 weekly 0.7 https://trial.medpath.com/news/ionis-announces-fda-acceptance-of-new-drug-application-for-donidalorsen-for-prophylactic-treatment-of-hae 2024-11-04T23:11:42+00:00 weekly 0.7 https://trial.medpath.com/news/dupilumab-reduces-itch-in-chronic-spontaneous-urticaria-in-phase-3-data-hcplive 2024-11-04T23:06:29+00:00 weekly 0.7 https://trial.medpath.com/news/first-of-a-kind-case-study-shows-remarkable-improvements-for-prostate-cancer-patient 2024-11-04T23:01:58+00:00 weekly 0.7 https://trial.medpath.com/news/simbiosys-achieves-second-fda-clearance-for-tumorsighttm-viz-and-longview-news-journal 2024-11-04T22:54:16+00:00 weekly 0.7 https://trial.medpath.com/news/another-arrow-to-the-quiver-for-physicians-fda-approves-emrosi-for-rosacea-healio 2024-11-04T22:48:40+00:00 weekly 0.7 https://trial.medpath.com/news/adverum-biotechnologies-inc-sec-10-q-report-tradingview 2024-11-04T22:31:34+00:00 weekly 0.7 https://trial.medpath.com/news/simbiosys-achieves-second-fda-clearance-for-tumorsighttm-viz-and-introduces-pr-newswire 2024-11-04T22:25:01+00:00 weekly 0.7 https://trial.medpath.com/news/precision-biosciences-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-04T22:02:40+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-director-steven-chaouki-buys-55553-in-shares-investing-com 2024-11-04T22:00:36+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-director-luput-acquires-shares-worth-55553-investing-com 2024-11-04T21:52:56+00:00 weekly 0.7 https://trial.medpath.com/news/aquestive-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-04T21:48:49+00:00 weekly 0.7 https://trial.medpath.com/news/unity-biotechnology-inc-reports-third-quarter-2024-globenewswire 2024-11-04T21:39:08+00:00 weekly 0.7 https://trial.medpath.com/news/unity-biotechnology-inc-reports-third-quarter-2024-financial-results-and-business-updates 2024-11-04T21:38:00+00:00 weekly 0.7 https://trial.medpath.com/news/unity-biotechnology-inc-reports-third-quarter-2024-financial-results-and-business-updates 2024-11-04T21:34:58+00:00 weekly 0.7 https://trial.medpath.com/news/neuropace-announces-fda-submission-of-three-year-data-from-post-approval-study-of 2024-11-04T21:16:09+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-option-for-rosacea-medpage-today 2024-11-04T21:15:35+00:00 weekly 0.7 https://trial.medpath.com/news/fda-breakthrough-therapy-designation-shows-38-7-approval-rate-with-317-products-receiving-market-authorization 2024-11-04T21:12:15+00:00 weekly 0.7 https://trial.medpath.com/news/neuropace-announces-fda-submission-of-three-year-data-from-globenewswire 2024-11-04T21:07:11+00:00 weekly 0.7 https://trial.medpath.com/news/novel-gene-therapy-for-neovascular-age-related-macular-degeneration-medpage-today 2024-11-04T21:00:33+00:00 weekly 0.7 https://trial.medpath.com/news/lsd-the-bad-and-potentially-good-sides-psychology-today 2024-11-04T20:57:48+00:00 weekly 0.7 https://trial.medpath.com/news/letter-warns-clinicians-of-severe-infections-with-pralsetinib-for-nsclc 2024-11-04T20:37:56+00:00 weekly 0.7 https://trial.medpath.com/news/new-found-gold-pulls-high-grade-gold-out-of-queensway-project-in-newfoundland 2024-11-04T20:28:42+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-trial-of-tavneos-enrolling-children-ages-6-17-with-aav-anca-vasculitis-news 2024-11-04T20:25:30+00:00 weekly 0.7 https://trial.medpath.com/news/a-crazy-idea-for-treating-autoimmune-diseases-might-actually-work-the-atlantic 2024-11-04T20:13:01+00:00 weekly 0.7 https://trial.medpath.com/news/disc-teases-potential-nda-for-rare-skin-disorder-drug-clinical-trials-arena 2024-11-04T20:07:27+00:00 weekly 0.7 https://trial.medpath.com/news/philips-enrolls-first-patient-in-u-s-clinical-trial-for-globenewswire 2024-11-04T19:58:31+00:00 weekly 0.7 https://trial.medpath.com/news/shockwave-medical-s-javelin-ivl-catheter-meets-primary-trial-endpoints-massdevice 2024-11-04T19:54:07+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-r3-vascular-ide-approval-for-elite-btk-pivotal-trial-of-its-magnitude-r-drug 2024-11-04T19:44:48+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-approves-ide-application-for-katana-thrombectomy-system-venous-news 2024-11-04T19:40:52+00:00 weekly 0.7 https://trial.medpath.com/news/roflumilast-reduces-disease-impact-of-atopic-dermatitis-hcplive 2024-11-04T19:33:52+00:00 weekly 0.7 https://trial.medpath.com/news/cytodyn-announces-fda-clearance-of-its-phase-ii-oncology-trial-globenewswire 2024-11-04T19:33:29+00:00 weekly 0.7 https://trial.medpath.com/news/enhancing-diversity-and-accessibility-in-clinical-trials-for-alzheimer-disease-neurologylive 2024-11-04T19:04:56+00:00 weekly 0.7 https://trial.medpath.com/news/the-state-of-the-art-of-n-of-1-therapies-and-the-irdirc-n-of-1-development-roadmap 2024-11-04T18:58:12+00:00 weekly 0.7 https://trial.medpath.com/news/unexpected-immunotherapy-success-in-rare-pancreatic-cancer-news-medical 2024-11-04T18:40:10+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-forges-new-standard-of-care-for-advanced-hodgkin-lymphoma-inventum 2024-11-04T18:23:21+00:00 weekly 0.7 https://trial.medpath.com/news/new-funding-drives-a-slew-of-breast-cancer-studies-fred-hutchinson-cancer-center 2024-11-04T18:18:31+00:00 weekly 0.7 https://trial.medpath.com/news/semaglutide-2-4-mg-shows-superior-improvement-in-liver-fibrosis-mash-resolution-in 2024-11-04T18:15:01+00:00 weekly 0.7 https://trial.medpath.com/news/journey-medical-corporation-announces-u-s-fda-approval-of-emrositm-minocycline 2024-11-04T18:13:17+00:00 weekly 0.7 https://trial.medpath.com/news/predicinecaretm-liquid-biopsy-assay-featured-in-nejm-as-pivotal-tool-in-roche-s-phase 2024-11-04T18:11:47+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-donidalorsen-nda-for-prophylactic-hereditary-angioedema 2024-11-04T18:11:24+00:00 weekly 0.7 https://trial.medpath.com/news/urticaria-clinical-trial-pipeline-accelerates-20-leading-globenewswire 2024-11-04T18:03:31+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-validation-of-an-ai-based-pathology-tool-for-scoring-of-metabolic-dysfunction 2024-11-04T18:00:49+00:00 weekly 0.7 https://trial.medpath.com/news/deferiprone-in-alzheimer-disease-a-randomized-clinical-trial-jama-network 2024-11-04T17:58:25+00:00 weekly 0.7 https://trial.medpath.com/news/novo-s-semaglutide-scores-in-liver-fibrosis-and-mash-trial-inside-precision-medicine 2024-11-04T17:56:49+00:00 weekly 0.7 https://trial.medpath.com/news/predicinecaretm-liquid-biopsy-assay-featured-in-nejm-as-pivotal-tool-in-roche-s-phase-iii 2024-11-04T17:52:53+00:00 weekly 0.7 https://trial.medpath.com/news/predicinecaretm-liquid-biopsy-assay-featured-in-nejm-as-globenewswire 2024-11-04T17:44:52+00:00 weekly 0.7 https://trial.medpath.com/news/100-biomarker-lab-test-for-alzheimer-s-disease-developed-by-team-at-university-of-pittsburgh 2024-11-04T17:43:20+00:00 weekly 0.7 https://trial.medpath.com/news/phaxiam-fda-green-light-for-phase-ii-study-marketscreener 2024-11-04T17:40:46+00:00 weekly 0.7 https://trial.medpath.com/news/ionis-announces-fda-acceptance-of-new-drug-application-for-donidalorsen-for-prophylactic 2024-11-04T17:39:03+00:00 weekly 0.7 https://trial.medpath.com/news/spectral-medical-provides-october-tigris-trial-update-globenewswire 2024-11-04T17:34:15+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-clearance-for-study-of-envoy-medical-s-cochlear-implant-yahoo 2024-11-04T17:24:42+00:00 weekly 0.7 https://trial.medpath.com/news/teva-s-long-lasting-schizophrenia-injectable-shines-in-phase-iii-clinical-trials-arena 2024-11-04T17:24:08+00:00 weekly 0.7 https://trial.medpath.com/news/sagimet-planning-phase-3-trials-of-denifanstat-in-mash-masld-liver-disease-news 2024-11-04T17:20:51+00:00 weekly 0.7 https://trial.medpath.com/news/ela026-receives-orphan-drug-designation-to-treat-hemophagocytic-lymphohistiocytosis 2024-11-04T17:19:24+00:00 weekly 0.7 https://trial.medpath.com/news/phaxiam-therapeutics-receives-fda-clearance-to-initiate-phase-ii-gloria-study-in-the-u-s 2024-11-04T17:04:33+00:00 weekly 0.7 https://trial.medpath.com/news/phaxiam-therapeutics-receives-fda-clearance-to-initiate-phase-ii-gloria-study-in-the-u-s 2024-11-04T17:03:34+00:00 weekly 0.7 https://trial.medpath.com/news/r3-vascular-wins-fda-ide-for-drug-eluting-scaffold-massdevice 2024-11-04T16:54:18+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-drug-hailed-as-major-breakthrough-could-actually-triple-risk-of-dying-ucl-news 2024-11-04T16:48:09+00:00 weekly 0.7 https://trial.medpath.com/news/polypid-shares-rise-on-strong-phase-3-prospects-gets-buy-rating-investing-com 2024-11-04T16:41:45+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-combination-may-demonstrate-benefit-in-patients-with-cutaneous-melanoma 2024-11-04T16:34:43+00:00 weekly 0.7 https://trial.medpath.com/news/results-of-elevatim-show-improvement-in-diabetic-macular-edema-with-vabysmo-for 2024-11-04T16:32:38+00:00 weekly 0.7 https://trial.medpath.com/news/viking-therapeutics-presents-positive-data-from-vk2735-for-reducing-body-weight 2024-11-04T16:23:57+00:00 weekly 0.7 https://trial.medpath.com/news/valemetostat-in-relapsed-or-refractory-peripheral-t-cell-lymphoma-the-asco-post 2024-11-04T16:20:17+00:00 weekly 0.7 https://trial.medpath.com/news/lasofoxifene-suppresses-ki-67-expression-in-hr-her2-early-stage-breast-cancer 2024-11-04T16:19:49+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-shr-a1811-plus-pyrotinib-shows-preliminary-efficacy-safety-in-her2-breast-cancer 2024-11-04T16:19:49+00:00 weekly 0.7 https://trial.medpath.com/news/bxq-350-is-well-tolerated-shows-clinical-activity-in-advanced-solid-tumors-onclive 2024-11-04T16:19:48+00:00 weekly 0.7 https://trial.medpath.com/news/sutro-biopharma-begins-trial-of-acute-myeloid-leukaemia-treatment-in-children 2024-11-04T16:11:32+00:00 weekly 0.7 https://trial.medpath.com/news/key-fda-decisions-made-in-2024-news-medical 2024-11-04T16:10:58+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-quanta-home-hemodialysis-system-massdevice 2024-11-04T16:09:52+00:00 weekly 0.7 https://trial.medpath.com/news/radiprodil-in-tsc-and-fcd-targeting-seizures-through-nmda-modulation-neurologylive 2024-11-04T16:09:40+00:00 weekly 0.7 https://trial.medpath.com/news/cilta-cel-may-outperform-standard-care-for-relapsed-refractory-myeloma 2024-11-04T16:06:50+00:00 weekly 0.7 https://trial.medpath.com/news/first-patients-dosed-in-new-phase-3-trials-of-dato-dxd-in-nsclc-targeted-oncology 2024-11-04T16:01:50+00:00 weekly 0.7 https://trial.medpath.com/news/clofutriben-receives-fda-orphan-drug-designation-to-treat-endogenous-cushing-syndrome 2024-11-04T15:51:20+00:00 weekly 0.7 https://trial.medpath.com/news/ventus-therapeutics-announces-positive-phase-1-trial-results-for-investigational-drug 2024-11-04T15:44:50+00:00 weekly 0.7 https://trial.medpath.com/news/raymond-james-increases-disc-medicine-shares-to-strong-buy-on-new-drug-investing-com 2024-11-04T15:42:57+00:00 weekly 0.7 https://trial.medpath.com/news/viking-therapeutics-weight-loss-pill-outperforms-ozempic-marker-novo-nordisk-s-quartz 2024-11-04T15:41:01+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-grants-r3-vascular-ide-approval-for-elite-btk-pivotal-trial-of-magnitude-drug 2024-11-04T15:39:52+00:00 weekly 0.7 https://trial.medpath.com/news/new-guselkumab-data-indicate-robust-effectiveness-in-crohn-disease-plaque-psoriasis 2024-11-04T15:34:33+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-journey-medical-s-dfd-29-for-rosacea-dermatology-times 2024-11-04T15:24:58+00:00 weekly 0.7 https://trial.medpath.com/news/fda-lifts-clinical-holds-placed-on-3-car-t-cell-therapy-trials-targeted-oncology 2024-11-04T15:21:55+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-approval-to-commence-trial-of-r3-vascular-s-scaffold-medical-device-network 2024-11-04T15:16:37+00:00 weekly 0.7 https://trial.medpath.com/news/implant-could-prevent-opioid-overdose-deaths-news-center 2024-11-04T15:12:09+00:00 weekly 0.7 https://trial.medpath.com/news/saint-itbs-protocol-shows-promise-for-bipolar-i-depression-psychiatric-times 2024-11-04T15:04:23+00:00 weekly 0.7 https://trial.medpath.com/news/ionis-announces-fda-acceptance-of-new-drug-application-for-donidalorsen-for-prophylactic 2024-11-04T14:58:07+00:00 weekly 0.7 https://trial.medpath.com/news/parkinson-disease-therapy-current-strategies-and-future-research-priorities-nature 2024-11-04T14:57:53+00:00 weekly 0.7 https://trial.medpath.com/news/ionis-announces-fda-acceptance-of-new-drug-application-for-donidalorsen-for-prophylactic 2024-11-04T14:56:27+00:00 weekly 0.7 https://trial.medpath.com/news/ionis-announces-fda-acceptance-of-new-drug-application-for-donidalorsen-for-prophylactic 2024-11-04T14:51:01+00:00 weekly 0.7 https://trial.medpath.com/news/small-molecules-sustaining-big-pharma-a-look-at-some-recent-headlines-the-medicine-maker 2024-11-04T14:47:26+00:00 weekly 0.7 https://trial.medpath.com/news/akura-medical-secures-fda-approval-for-us-pivotal-trial-in-pulmonary 2024-11-04T14:41:28+00:00 weekly 0.7 https://trial.medpath.com/news/philips-enrolls-first-patient-in-u-s-clinical-trial-for-innovative-integrated-single-device-to-treat 2024-11-04T14:36:44+00:00 weekly 0.7 https://trial.medpath.com/news/dosing-begins-in-early-clinical-trial-of-lucid-ms-to-protect-myelin-sheath 2024-11-04T14:36:14+00:00 weekly 0.7 https://trial.medpath.com/news/viking-therapeutics-shines-with-promising-results-for-new-obesity-drug-finimize 2024-11-04T14:34:23+00:00 weekly 0.7 https://trial.medpath.com/news/prehabilitative-rehabilitative-exercise-nutrition-and-psychological-support-for-bladder-cancer 2024-11-04T14:27:11+00:00 weekly 0.7 https://trial.medpath.com/news/neuraxis-receives-new-fda-510-k-clearance-for-ib-stim-expanding-its-addressable-market 2024-11-04T14:25:27+00:00 weekly 0.7 https://trial.medpath.com/news/akura-medical-secures-fda-approval-for-us-pivotal-trial-in-pulmonary 2024-11-04T14:22:04+00:00 weekly 0.7 https://trial.medpath.com/news/neuraxis-receives-new-fda-510-k-clearance-for-ib-stim-expanding-its-addressable-market 2024-11-04T14:11:53+00:00 weekly 0.7 https://trial.medpath.com/news/che-negatively-impacts-quality-of-life-according-to-patients-dermatology-times 2024-11-04T14:09:59+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-minocycline-hydrochloride-extended-release-capsules-for-individuals-with-rosacea 2024-11-04T14:08:00+00:00 weekly 0.7 https://trial.medpath.com/news/cytodyn-announces-fda-clearance-of-its-phase-ii-oncology-trial-nation-world 2024-11-04T13:54:45+00:00 weekly 0.7 https://trial.medpath.com/news/cvrx-earns-medicare-win-for-barostim-procedure-massdevice 2024-11-04T13:53:47+00:00 weekly 0.7 https://trial.medpath.com/news/journey-medical-fda-approves-emrosi-for-treatment-of-inflammatory-lesions-of-rosacea 2024-11-04T13:43:25+00:00 weekly 0.7 https://trial.medpath.com/news/krystal-biotech-inc-sec-10-q-report-tradingview 2024-11-04T13:41:00+00:00 weekly 0.7 https://trial.medpath.com/news/regorafenib-shows-survival-benefit-in-late-stage-gastric-cancer-integrate-iia-trial 2024-11-04T13:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/cervomed-announces-key-takeaways-from-oral-presentations-at-the-17th-clinical-trials-on 2024-11-04T13:27:19+00:00 weekly 0.7 https://trial.medpath.com/news/essa-pharma-downgraded-by-oppenheimer-piper-sandler-after-drug-setback-in-trials 2024-11-04T13:23:01+00:00 weekly 0.7 https://trial.medpath.com/news/spectral-medical-provides-october-tigris-trial-update-financial-post 2024-11-04T13:20:45+00:00 weekly 0.7 https://trial.medpath.com/news/cervomed-announces-key-takeaways-from-oral-presentations-at-the-17th-clinical-trials-on 2024-11-04T13:14:26+00:00 weekly 0.7 https://trial.medpath.com/news/mhra-approves-cstone-pharmaceuticals-sugemalimab-to-treat-lung-cancer-in-adults 2024-11-04T13:12:11+00:00 weekly 0.7 https://trial.medpath.com/news/leo-pharma-shares-final-long-term-results-for-atopic-dermatitis-drug-adbry-pmlive 2024-11-04T13:12:10+00:00 weekly 0.7 https://trial.medpath.com/news/patients-achieve-insulin-freedom-with-tegoprubart-immunotherapy 2024-11-04T13:11:22+00:00 weekly 0.7 https://trial.medpath.com/news/key-trials-on-parp-inhibitor-combinations-in-metastatic-prostate-cancer-urology-times 2024-11-04T13:06:13+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-data-shows-long-term-efficacy-safety-of-stapokibart-for-atopic-dermatitis 2024-11-04T13:03:48+00:00 weekly 0.7 https://trial.medpath.com/news/cervomed-announces-key-takeaways-from-oral-presentations-at-globenewswire 2024-11-04T13:02:51+00:00 weekly 0.7 https://trial.medpath.com/news/spectral-medical-provides-october-tigris-trial-update-globenewswire 2024-11-04T13:02:46+00:00 weekly 0.7 https://trial.medpath.com/news/neurobo-pharmaceuticals-completes-last-patient-last-visit-in-its-phase-2a-clinical-trial 2024-11-04T13:02:13+00:00 weekly 0.7 https://trial.medpath.com/news/kazia-therapeutics-announces-granting-of-type-c-meeting-with-fda-to-discuss-potential 2024-11-04T13:00:04+00:00 weekly 0.7 https://trial.medpath.com/news/teva-s-tev-749-yields-positive-results-in-phase-3-schizophrenia-trial 2024-11-04T12:55:43+00:00 weekly 0.7 https://trial.medpath.com/news/disc-medicine-announces-successful-end-of-phase-2-meeting-globenewswire 2024-11-04T12:53:44+00:00 weekly 0.7 https://trial.medpath.com/news/angitia-biopharmaceuticals-announces-dosing-of-first-globenewswire 2024-11-04T12:47:17+00:00 weekly 0.7 https://trial.medpath.com/news/record-monthly-enrollment-achieved-in-seastar-medical-s-pivotal-adult-aki-trial-biospace 2024-11-04T12:40:47+00:00 weekly 0.7 https://trial.medpath.com/news/memo-therapeutics-ag-announces-last-patient-enrolled-in-phase-ii-clinical-trial-of-biospace 2024-11-04T12:40:47+00:00 weekly 0.7 https://trial.medpath.com/news/ideaya-biosciences-inc-reports-third-quarter-2024-financial-results-and-provides 2024-11-04T12:40:46+00:00 weekly 0.7 https://trial.medpath.com/news/verona-pharma-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-04T12:40:46+00:00 weekly 0.7 https://trial.medpath.com/news/journey-medical-announces-u-s-fda-approval-of-emrositm-minocycline-hydrochloride 2024-11-04T12:35:11+00:00 weekly 0.7 https://trial.medpath.com/news/kazia-therapeutics-announces-granting-of-type-c-meeting-with-fda-to-discuss-potential 2024-11-04T12:34:09+00:00 weekly 0.7 https://trial.medpath.com/news/biontech-announces-third-quarter-2024-financial-results-and-corporate-update 2024-11-04T12:29:19+00:00 weekly 0.7 https://trial.medpath.com/news/tonix-pharmaceuticals-announces-research-agreement-with-kenya-medical-morningstar 2024-11-04T12:29:12+00:00 weekly 0.7 https://trial.medpath.com/news/cytosorbents-submits-health-canada-medical-device-license-application-for-drugsorb 2024-11-04T12:29:12+00:00 weekly 0.7 https://trial.medpath.com/news/philips-enrolls-first-patient-in-u-s-clinical-trial-to-study-highly-innovative-single-device 2024-11-04T12:18:38+00:00 weekly 0.7 https://trial.medpath.com/news/can-fite-anti-obesity-drug-namodenoson-received-patent-allowance-in-australia 2024-11-04T12:11:01+00:00 weekly 0.7 https://trial.medpath.com/news/dri-healthcare-trust-announces-acquisition-of-a-synthetic-royalty-interest-in-the-markets-data 2024-11-04T12:09:30+00:00 weekly 0.7 https://trial.medpath.com/news/european-medicines-agency-confirms-acceptance-of-marketing-authorization-yahoo-finance 2024-11-04T12:08:05+00:00 weekly 0.7 https://trial.medpath.com/news/european-medicines-agency-confirms-acceptance-of-marketing-authorization-yahoo-finance 2024-11-04T12:08:01+00:00 weekly 0.7 https://trial.medpath.com/news/european-medicines-agency-confirms-acceptance-of-marketing-globenewswire 2024-11-04T12:04:11+00:00 weekly 0.7 https://trial.medpath.com/news/atossa-therapeutics-reports-positive-karisma-endoxifen-trial-results-globenewswire 2024-11-04T11:41:31+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-r3-vascular-ide-approval-for-elite-btk-pivotal-trial-of-its-magnitude-r-drug 2024-11-04T11:21:02+00:00 weekly 0.7 https://trial.medpath.com/news/100-biomarker-lab-test-for-alzheimer-s-disease-developed-by-team-at-university-of-pittsburgh 2024-11-04T11:07:35+00:00 weekly 0.7 https://trial.medpath.com/news/formosa-pharmaceuticals-announces-successful-top-line-results-from-cpn-303-a-phase 2024-11-04T11:01:11+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-reports-positive-data-from-part-one-of-semaglutide-trial-for-mash 2024-11-04T10:40:58+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-clearance-for-study-of-envoy-medical-s-cochlear-implant 2024-11-04T10:21:00+00:00 weekly 0.7 https://trial.medpath.com/news/shanghai-fosun-pharma-announces-drug-registration-acceptance-tipranks-com 2024-11-04T10:19:13+00:00 weekly 0.7 https://trial.medpath.com/news/korean-dementia-association-leqembi-s-side-effects-are-not-significant-komedidaskeom 2024-11-04T09:50:00+00:00 weekly 0.7 https://trial.medpath.com/news/grand-pharmaceutical-s-breakthrough-in-ophthalmic-drug-trial-tipranks-com 2024-11-04T09:24:13+00:00 weekly 0.7 https://trial.medpath.com/news/shandong-xinhua-pharmaceutical-gains-key-drug-approval-tipranks-com 2024-11-04T09:15:22+00:00 weekly 0.7 https://trial.medpath.com/news/shandong-xinhua-pharmaceutical-gains-approval-for-pentazocine-tipranks-com 2024-11-04T09:15:22+00:00 weekly 0.7 https://trial.medpath.com/news/jongkundang-receives-fda-approval-for-phase-1-clinical-trial-of-new-hyperlipidemia-treatment 2024-11-04T09:13:28+00:00 weekly 0.7 https://trial.medpath.com/news/pharmacists-take-leading-role-in-combating-medical-misinformation-through-evidence-based-strategies 2024-11-04T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/multiscale-mechanistic-model-of-rheumatoid-arthritis-to-enable-decision-making-in-late 2024-11-04T08:30:31+00:00 weekly 0.7 https://trial.medpath.com/news/verastem-oncology-submits-nda-to-us-fda-for-avutometinib-plus-defactinib-to-treat-pharmabiz 2024-11-04T08:29:22+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-will-file-semaglutide-for-mash-next-year-pharmaphorum 2024-11-04T07:36:24+00:00 weekly 0.7 https://trial.medpath.com/news/medincell-s-partner-teva-unveils-new-phase-3-positive-results-for-olanzapine-lai-and 2024-11-04T07:28:40+00:00 weekly 0.7 https://trial.medpath.com/news/verona-pharma-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-04T07:19:58+00:00 weekly 0.7 https://trial.medpath.com/news/verona-pharma-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-04T07:18:01+00:00 weekly 0.7 https://trial.medpath.com/news/verona-pharma-reports-third-quarter-2024-financial-results-globenewswire 2024-11-04T07:11:30+00:00 weekly 0.7 https://trial.medpath.com/news/qiagen-receives-fda-clearance-of-qiastat-dx-meningitis-encephalitis-panel-to-support 2024-11-04T07:05:09+00:00 weekly 0.7 https://trial.medpath.com/news/qiagen-receives-fda-clearance-of-qiastat-dx-globenewswire 2024-11-04T06:48:35+00:00 weekly 0.7 https://trial.medpath.com/news/qiagen-receives-fda-clearance-of-qiastat-dx-meningitis-encephalitis-panel-to-support 2024-11-04T06:48:12+00:00 weekly 0.7 https://trial.medpath.com/news/qiagen-receives-fda-clearance-of-qiastat-dx-meningitis-encephalitis-panel-to-support 2024-11-04T06:40:33+00:00 weekly 0.7 https://trial.medpath.com/news/qiagen-receives-fda-clearance-of-qiastat-dx-meningitis-encephalitis-panel-to-support 2024-11-04T06:38:38+00:00 weekly 0.7 https://trial.medpath.com/news/prokarium-secures-two-us-patents-for-novel-cancer-immunotherapy-platform 2024-11-04T06:08:17+00:00 weekly 0.7 https://trial.medpath.com/news/pioneering-gene-therapies-coming-from-zayed-centre-breakthroughs-the-national 2024-11-04T06:04:20+00:00 weekly 0.7 https://trial.medpath.com/news/experts-call-for-paradigm-shift-in-cancer-drug-dosing-moving-beyond-maximum-tolerated-dose 2024-11-04T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cytoki-pharma-announces-first-patient-dosed-in-phase-2-study-of-ck-0045-in-obesity-and 2024-11-04T05:32:16+00:00 weekly 0.7 https://trial.medpath.com/news/nanoviricides-to-provide-corporate-update-at-the-spartan-capital-investors-conference 2024-11-04T05:32:11+00:00 weekly 0.7 https://trial.medpath.com/news/actinogen-medical-advances-in-neurological-drug-development-markets-insider 2024-11-04T05:25:50+00:00 weekly 0.7 https://trial.medpath.com/news/fda-action-alert-journey-merus-ptc-and-autolus-biospace 2024-11-04T05:07:25+00:00 weekly 0.7 https://trial.medpath.com/news/7-alzheimer-s-and-parkinson-s-programs-discarded-in-2024-biospace 2024-11-04T05:07:24+00:00 weekly 0.7 https://trial.medpath.com/news/cipla-share-price-rises-11-in-three-sessions-as-brokerages-positive-on-us-fda-clearance 2024-11-04T04:53:16+00:00 weekly 0.7 https://trial.medpath.com/news/successful-treatment-of-pediatric-generalized-pustular-psoriasis-gpp-dove-medical-press 2024-11-04T04:51:01+00:00 weekly 0.7 https://trial.medpath.com/news/court-blocks-sun-pharma-s-alopecia-drug-launch-following-incyte-patent-dispute 2024-11-04T04:27:44+00:00 weekly 0.7 https://trial.medpath.com/news/endevica-bio-launches-abisati-to-advance-novel-obesity-drug-710go-into-clinical-trials 2024-11-04T04:12:33+00:00 weekly 0.7 https://trial.medpath.com/news/iisc-gets-rs-52-47-crore-under-ayurswasthya-yojna-for-coe-in-ayurveda-for-diabetes-and 2024-11-04T02:30:16+00:00 weekly 0.7 https://trial.medpath.com/news/first-in-human-phase-1-dose-escalation-and-dose-expansion-study-of-a-ret-inhibitor-sy-nature 2024-11-04T01:08:32+00:00 weekly 0.7 https://trial.medpath.com/news/a-round-up-of-alzheimer-s-drug-trials-news-from-ctad-2024-being-patient 2024-11-04T01:03:42+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-emrosi-minocycline-hydrochloride-for-the-treatment-of-rosacea 2024-11-04T00:11:22+00:00 weekly 0.7 https://trial.medpath.com/news/journey-medical-corporation-reports-second-quarter-2024-financial-results-and-recent-corporate-highlights 2024-11-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/hanall-biopharma-reports-q3-2024-financial-results-and 2024-11-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-digital-health-behavior-intervention-to-prevent-childhood-obesity-jama-network 2024-11-03T22:55:14+00:00 weekly 0.7 https://trial.medpath.com/news/kazia-therapeutics-corporate-presentation-november-2024-marketscreener 2024-11-03T21:44:33+00:00 weekly 0.7 https://trial.medpath.com/news/unified-clinical-platforms-drive-efficiency-in-drug-development-through-strategic-it-models 2024-11-03T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-select-trial-analysis-with-semaglutide-2-4-mg-showed-a-significant-reduction-morningstar 2024-11-03T20:46:31+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-progression-may-be-slowed-by-targeted-magnetic-pulses-study-suggests 2024-11-03T20:46:25+00:00 weekly 0.7 https://trial.medpath.com/news/graphene-chip-implant-in-uk-trial-could-transform-brain-tumour-surgery-the-guardian 2024-11-03T20:29:11+00:00 weekly 0.7 https://trial.medpath.com/news/adjunctive-antipsychotic-helps-ease-symptoms-of-depression-medpage-today 2024-11-03T20:16:50+00:00 weekly 0.7 https://trial.medpath.com/news/intas-pharmaceutical-gets-cdsco-panels-nod-to-conduct-phase-iii-clinical-trial-of-ruxolitinib-cream 2024-11-03T20:05:18+00:00 weekly 0.7 https://trial.medpath.com/news/leukocytes-telomere-length-as-a-biomarker-of-adverse-drug-reactions-induced-by-nature 2024-11-03T20:03:05+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-healthcare-gets-cdsco-panel-nod-to-study-asthma-drug-sar443765 2024-11-03T19:54:34+00:00 weekly 0.7 https://trial.medpath.com/news/contributor-the-era-of-disease-modifying-alzheimer-disease-treatments 2024-11-03T19:43:55+00:00 weekly 0.7 https://trial.medpath.com/news/rheumatology-month-in-review-october-2024-hcplive 2024-11-03T19:10:46+00:00 weekly 0.7 https://trial.medpath.com/news/marking-a-new-era-in-patient-care-with-advancements-in-disease-modifying-alzheimer-treatments 2024-11-03T19:04:30+00:00 weekly 0.7 https://trial.medpath.com/news/nda-filed-for-avutometinib-plus-defactinib-for-low-grade-serous-ovarian-cancer 2024-11-03T18:09:26+00:00 weekly 0.7 https://trial.medpath.com/news/cinfina-pharma-presents-positive-phase-1-study-results-in-poster-session-for-cin-109-and 2024-11-03T17:20:45+00:00 weekly 0.7 https://trial.medpath.com/news/flasco-fall-session-advancements-in-mrd-monitoring-using-ctdna-in-lung-cancer 2024-11-03T17:04:34+00:00 weekly 0.7 https://trial.medpath.com/news/twice-yearly-lenacapavir-may-change-the-world-if-we-make-it-work-contagion-live 2024-11-03T16:59:33+00:00 weekly 0.7 https://trial.medpath.com/news/sutro-biopharma-announces-initiation-of-the-registration-enabling-reframe-p1-trial-with 2024-11-03T15:47:55+00:00 weekly 0.7 https://trial.medpath.com/news/induction-chemotherapy-combination-boosts-pfs-os-in-cervical-cancer 2024-11-03T15:07:13+00:00 weekly 0.7 https://trial.medpath.com/news/caroline-diorio-md-frcpc-faap-on-noninflammatory-neurotoxicity-events-in-patients 2024-11-03T14:20:41+00:00 weekly 0.7 https://trial.medpath.com/news/implications-of-findings-on-patient-reported-outcomes-for-roflumilast-foam-with-melinda 2024-11-03T14:01:18+00:00 weekly 0.7 https://trial.medpath.com/news/new-psychiatric-technique-asks-schizophrenics-to-engage-in-dialogue-with-the-voices-futurism 2024-11-03T13:54:25+00:00 weekly 0.7 https://trial.medpath.com/news/why-sun-pharma-may-be-in-focus-on-monday-cnbc-tv18 2024-11-03T13:39:18+00:00 weekly 0.7 https://trial.medpath.com/news/comparison-of-bilicocoon-phototherapy-with-overhead-phototherapy-in-hyperbilirubinemic 2024-11-03T13:19:19+00:00 weekly 0.7 https://trial.medpath.com/news/role-of-tumor-specific-and-whole-body-imaging-biomarkers-for-prediction-of-recurrence-in 2024-11-03T13:04:39+00:00 weekly 0.7 https://trial.medpath.com/news/shuttle-pharmaceuticals-holds-public-offering-to-advance-clinical-trials-defense-world 2024-11-03T12:08:59+00:00 weekly 0.7 https://trial.medpath.com/news/the-targeted-pulse-uncover-the-latest-from-wclc-and-experts-insights-into-latest 2024-11-03T12:01:31+00:00 weekly 0.7 https://trial.medpath.com/news/earnings-call-takeda-reports-robust-h1-growth-revises-full-year-guidance-investing-com 2024-11-03T11:12:49+00:00 weekly 0.7 https://trial.medpath.com/news/shr-a1921-demonstrates-early-efficacy-in-platinum-resistant-ovarian-cancer-onclive 2024-11-03T11:09:14+00:00 weekly 0.7 https://trial.medpath.com/news/the-r-o-a-d-to-precision-medicine-nature 2024-11-03T09:40:29+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-alpha-1-antitrypsin-deficiency-aatd-nct06622668-crispr-medicine 2024-11-03T09:25:28+00:00 weekly 0.7 https://trial.medpath.com/news/16-hospitals-test-potentially-life-saving-device-designed-for-indian-stroke-patients 2024-11-03T09:23:58+00:00 weekly 0.7 https://trial.medpath.com/news/debra-miller-los-angeles-times 2024-11-03T09:05:45+00:00 weekly 0.7 https://trial.medpath.com/news/novel-anti-mdm2-protac-shows-promise-for-p53-mutated-cancer-treatment 2024-11-03T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/the-scientist-who-tested-his-revolutionary-medicine-on-his-own-brain-cancer-the-guardian 2024-11-03T07:36:18+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-evidence-for-pembrolizumab-in-non-small-cell-lung-cancer-a-nationwide-cohort-study 2024-11-03T07:15:29+00:00 weekly 0.7 https://trial.medpath.com/news/sermonix-pharmaceuticals-lasofoxifene-is-well-tolerated-demonstrates-promising-ki67 2024-11-03T05:06:35+00:00 weekly 0.7 https://trial.medpath.com/news/the-european-medicines-agency-approves-the-moderna-vaccine 2024-11-03T03:43:43+00:00 weekly 0.7 https://trial.medpath.com/news/innocare-pharma-sehk-9969-achieves-key-milestone-with-icp-488-phase-ii-success-in 2024-11-03T00:57:45+00:00 weekly 0.7 https://trial.medpath.com/news/mtnb-matinas-biopharma-holdings-inc-latest-stock-news-market-updates 2024-11-03T00:29:30+00:00 weekly 0.7 https://trial.medpath.com/news/driver-mutations-associated-with-signatures-of-platinum-sensitivity-in-germ-cell-tumors 2024-11-03T00:10:15+00:00 weekly 0.7 https://trial.medpath.com/news/semaglutide-shows-promise-for-osteoarthritis-pain-relief-the-pinnacle-gazette 2024-11-02T23:51:14+00:00 weekly 0.7 https://trial.medpath.com/news/hospital-tries-car-t-therapy-for-lung-cancer-shine-news-shanghai-daily 2024-11-02T23:28:57+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-of-xanomeline-and-trospium-chloride-in-schizophrenia-pooled-results-from-three-5 2024-11-02T23:14:04+00:00 weekly 0.7 https://trial.medpath.com/news/merus-annonce-ses-resultats-financiers-pour-le-troisieme-globenewswire 2024-11-02T22:20:32+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-solid-tumors-nct06598371-crispr-medicine-news 2024-11-02T21:30:25+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-hereditary-angioedema-hae-nct06634420-crispr-medicine-news 2024-11-02T21:30:21+00:00 weekly 0.7 https://trial.medpath.com/news/uk-s-nice-says-alzheimer-s-disease-drug-kisunla-is-not-cost-effective-forbes 2024-11-02T19:58:31+00:00 weekly 0.7 https://trial.medpath.com/news/bringing-precision-medicine-to-psychiatry-circular-rnas-as-a-window-into-the-brain-nature 2024-11-02T19:10:43+00:00 weekly 0.7 https://trial.medpath.com/news/hoping-for-a-weight-loss-pill-it-could-get-closer-to-reality-next-week-morningstar 2024-11-02T18:25:06+00:00 weekly 0.7 https://trial.medpath.com/news/gastroenterology-month-in-review-october-2024-hcplive 2024-11-02T18:03:39+00:00 weekly 0.7 https://trial.medpath.com/news/remission-rate-toxicity-and-pharmacokinetics-of-venetoclax-based-induction-regimens-in-nature 2024-11-02T17:45:04+00:00 weekly 0.7 https://trial.medpath.com/news/enhanced-dosing-of-donanemab-lowers-aria-risk-anti-tau-agent-e2814-shows 2024-11-02T17:08:55+00:00 weekly 0.7 https://trial.medpath.com/news/asco-seeks-to-expand-pharmacist-membership-and-engagement-in-oncology-standards-development 2024-11-02T16:53:24+00:00 weekly 0.7 https://trial.medpath.com/news/this-week-in-ophthalmology-week-of-october-26-2024 2024-11-02T16:37:13+00:00 weekly 0.7 https://trial.medpath.com/news/semaglutide-so-effective-at-treating-arthritis-that-patients-were-more-or-less-were-futurism 2024-11-02T16:36:07+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-policy-monitor-november-12-2024-aacr 2024-11-02T16:32:18+00:00 weekly 0.7 https://trial.medpath.com/news/madrigal-89bio-jump-after-novo-s-semaglutide-shows-promise-in-mash-yahoo-finance 2024-11-02T16:06:37+00:00 weekly 0.7 https://trial.medpath.com/news/guanxinning-for-residual-inflammation-of-stable-coronary-artery-diseas-dove-medical-press 2024-11-02T15:51:16+00:00 weekly 0.7 https://trial.medpath.com/news/bath-hospital-needs-volunteers-for-stroke-drug-study-bbc 2024-11-02T15:24:47+00:00 weekly 0.7 https://trial.medpath.com/news/fda-panel-votes-against-sotagliflozin-for-glucose-control-in-type-1-diabetes-ckd-healio 2024-11-02T14:04:22+00:00 weekly 0.7 https://trial.medpath.com/news/bravo-trial-highlights-improved-detection-reduces-bladder-cancer-recurrence-from-urotoday 2024-11-02T14:01:03+00:00 weekly 0.7 https://trial.medpath.com/news/omega-3-supplements-show-benefit-in-apoe4-carriers-medpage-today 2024-11-02T14:00:40+00:00 weekly 0.7 https://trial.medpath.com/news/is-it-really-cancer-more-concerns-about-accelerated-approval-metformin-and-cancer 2024-11-02T14:00:36+00:00 weekly 0.7 https://trial.medpath.com/news/compass-pathways-cuts-30-of-workforce-on-phase-3-trial-delays-yahoo-finance 2024-11-02T13:31:50+00:00 weekly 0.7 https://trial.medpath.com/news/pharma-stock-roundup-mrk-pfe-abbv-nvs-lly-s-q3-earnings-in-focus 2024-11-02T13:30:40+00:00 weekly 0.7 https://trial.medpath.com/news/benefit-of-systemic-therapy-in-mindact-patients-with-small-er-positive-her2-negative 2024-11-02T13:25:31+00:00 weekly 0.7 https://trial.medpath.com/news/sermonix-pharmaceuticals-lasofoxifene-is-well-tolerated-globenewswire 2024-11-02T13:16:29+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approved-drug-for-ulcerative-colitis-also-effective-for-crohn-s-medicalnewstoday 2024-11-02T13:12:52+00:00 weekly 0.7 https://trial.medpath.com/news/sermonix-pharmaceuticals-lasofoxifene-is-well-tolerated-demonstrates-promising-ki67 2024-11-02T13:10:50+00:00 weekly 0.7 https://trial.medpath.com/news/nyu-langone-health-in-the-news-friday-november-1-2024 2024-11-02T12:52:54+00:00 weekly 0.7 https://trial.medpath.com/news/oikn-partners-with-us-companies-to-develop-command-center-concept-antara-news 2024-11-02T12:14:36+00:00 weekly 0.7 https://trial.medpath.com/news/biosimilars-month-in-review-october-2024-hcplive 2024-11-02T12:03:59+00:00 weekly 0.7 https://trial.medpath.com/news/fda-panel-rejects-sglt1-2-inhibitor-for-type-1-diabetes-medpage-today 2024-11-02T11:52:09+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-researchers-say-brain-stimulation-device-may-slow-symptoms-nbc-news 2024-11-02T11:34:45+00:00 weekly 0.7 https://trial.medpath.com/news/essa-pharma-halts-phase-ii-study-of-masofaniten-in-prostate-cancer-treatment 2024-11-02T11:34:21+00:00 weekly 0.7 https://trial.medpath.com/news/vyn201-for-vitiligo-phase-1b-study-confirms-safety-dermatology-times 2024-11-02T11:16:38+00:00 weekly 0.7 https://trial.medpath.com/news/new-alzheimer-s-resource-center-opening-in-oak-cliff-cbs-news 2024-11-02T11:08:16+00:00 weekly 0.7 https://trial.medpath.com/news/phase-ii-trial-evaluating-the-long-term-efficacy-and-peripheral-sensory-neuropathy-of-nature 2024-11-02T11:02:57+00:00 weekly 0.7 https://trial.medpath.com/news/alx-oncology-announces-results-from-phase-1b-2-trial-of-globenewswire 2024-11-02T09:31:57+00:00 weekly 0.7 https://trial.medpath.com/news/lilly-to-present-results-from-phase-3-ember-3-study-of-imlunestrant-an-oral-serd-and 2024-11-02T09:30:38+00:00 weekly 0.7 https://trial.medpath.com/news/essa-discontinues-phase-2-study-of-masofaniten-plus-enzalutamide-in-mcrpc-onclive 2024-11-02T09:25:50+00:00 weekly 0.7 https://trial.medpath.com/news/indirect-comparison-shows-superiority-of-cilta-cel-vs-soc-regimens-in-lenalidomide 2024-11-02T09:25:50+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approval-sought-for-avutometinib-plus-defactinib-in-recurrent-kras-low-grade-onclive 2024-11-02T09:25:49+00:00 weekly 0.7 https://trial.medpath.com/news/cms-grants-transitional-pass-through-payment-for-medtronic-symplicity-spyraltm-renal 2024-11-02T09:24:41+00:00 weekly 0.7 https://trial.medpath.com/news/teva-presents-latest-schizophrenia-treatment-research-including-phase-3-solaris-trial 2024-11-02T08:39:07+00:00 weekly 0.7 https://trial.medpath.com/news/the-phase-iii-clinical-trial-application-for-first-line-treatment-of-extensive-disease-small-cell 2024-11-02T08:39:06+00:00 weekly 0.7 https://trial.medpath.com/news/oncoinvent-announces-publication-of-18-month-safety-and-efficacy-data-from-the-phase-1 2024-11-02T08:39:06+00:00 weekly 0.7 https://trial.medpath.com/news/disc-medicine-to-host-conference-call-on-end-of-phase-2-fda-globenewswire 2024-11-02T08:02:23+00:00 weekly 0.7 https://trial.medpath.com/news/infliximab-monotherapy-effective-as-combo-therapy-for-treating-inflammatory-bowel-disease 2024-11-02T07:52:20+00:00 weekly 0.7 https://trial.medpath.com/news/verastem-oncology-submits-nda-for-ovarian-cancer-treatment-pharmaceutical-technology 2024-11-02T07:21:55+00:00 weekly 0.7 https://trial.medpath.com/news/cgtlive-r-s-weekly-rewind-november-1-2024 2024-11-02T07:05:05+00:00 weekly 0.7 https://trial.medpath.com/news/less-frequent-elfabrio-dosing-for-fabry-disease-appears-to-be-safe-effective 2024-11-02T06:32:22+00:00 weekly 0.7 https://trial.medpath.com/news/blue-earth-therapeutics-reports-promising-phase-1-data-for-investigational-therapies 2024-11-02T06:25:49+00:00 weekly 0.7 https://trial.medpath.com/news/teva-presents-phase-3-solaris-trial-results-markets-insider 2024-11-02T06:03:38+00:00 weekly 0.7 https://trial.medpath.com/news/predicting-deterioration-in-dengue-using-a-low-cost-wearable-for-continuous-clinical-monitoring 2024-11-02T05:21:13+00:00 weekly 0.7 https://trial.medpath.com/news/bullous-pemphigoid-executive-insights-bullous-pemphigoid-executive-insights-us-eu5 2024-11-02T05:19:26+00:00 weekly 0.7 https://trial.medpath.com/news/ai-algorithm-shows-promise-in-early-detection-of-rare-blood-disorder-pnh 2024-11-02T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-cap-002-to-treat-patients-with-developmental-and 2024-11-02T04:40:54+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-glp-1-drug-meets-goals-of-mash-trial-setting-stage-for-fda-ema-filings 2024-11-02T04:31:49+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-drug-for-schizophrenia-promises-few-side-effects-straight-arrow-news 2024-11-02T04:16:05+00:00 weekly 0.7 https://trial.medpath.com/news/managing-amivantamab-s-complex-safety-profile-new-strategies-for-egfr-positive-nsclc-treatment 2024-11-02T04:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/rolling-nda-completed-for-avutometinib-combo-in-ovarian-cancer-subtype 2024-11-02T04:07:14+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approved-drug-for-ulcerative-colitis-also-effective-for-crohn-s-aol-com 2024-11-02T03:32:08+00:00 weekly 0.7 https://trial.medpath.com/news/fda-advisory-committee-votes-down-sotagliflozin-in-type-1-diabetes-and-ckd 2024-11-02T03:21:02+00:00 weekly 0.7 https://trial.medpath.com/news/rifaximin-reduced-overt-hepatic-encephalopathy-recurrence-over-lactulose 2024-11-02T03:18:17+00:00 weekly 0.7 https://trial.medpath.com/news/novel-immunotherapy-combo-shows-promise-in-melanoma-eurekalert 2024-11-02T02:42:34+00:00 weekly 0.7 https://trial.medpath.com/news/dkn-01-with-tislelizumab-and-chemotherapy-in-advanced-gastric-or-gastroesophageal 2024-11-02T02:41:40+00:00 weekly 0.7 https://trial.medpath.com/news/revisit-every-onclive-on-air-episode-from-october-2024 2024-11-02T02:18:19+00:00 weekly 0.7 https://trial.medpath.com/news/inavolisib-regimen-continues-to-improve-survival-in-pik3ca-mutated-breast-cancer 2024-11-02T02:18:11+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-critical-care-gaps-and-economic-burden-for-metastatic-bone-disease-patients 2024-11-02T02:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lexicon-stock-tumbles-after-fda-adcom-votes-against-zynquista-again 2024-11-02T01:21:56+00:00 weekly 0.7 https://trial.medpath.com/news/envoy-medical-receives-fda-approval-to-initiate-pivotal-clinical-study-for-breakthrough-hearing 2024-11-02T00:16:18+00:00 weekly 0.7 https://trial.medpath.com/news/atezolizumab-matched-targeted-therapy-improves-os-in-anaplastic-thyroid-cancer 2024-11-02T00:02:05+00:00 weekly 0.7 https://trial.medpath.com/news/wegovy-demonstrates-superiority-over-placebo-in-patients-with-metabolic-dysfunction 2024-11-01T23:53:15+00:00 weekly 0.7 https://trial.medpath.com/news/recor-medical-announces-cms-grant-of-transitional-pass-through-tpt-payment-tradingview 2024-11-01T23:35:42+00:00 weekly 0.7 https://trial.medpath.com/news/powerful-new-therapy-doubles-progression-free-survival-in-advanced-breast-cancer 2024-11-01T23:28:12+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-encouraging-results-in-her2-breast-cancer-with-brain-mets 2024-11-01T23:01:19+00:00 weekly 0.7 https://trial.medpath.com/news/court-denies-jazz-s-challenge-of-avadel-s-orphan-drug-lumryz-sleep-review 2024-11-01T22:39:53+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-cancer-treatment-implantable-microparticles-deliver-dual-therapies 2024-11-01T22:35:19+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-irhythm-s-second-510-k-in-response-to-warning-letter-medtech-dive 2024-11-01T22:29:05+00:00 weekly 0.7 https://trial.medpath.com/news/baili-tianheng-688506-rapid-promotion-of-innovation-pipeline-and-active-layout-of-yicai-global 2024-11-01T22:05:53+00:00 weekly 0.7 https://trial.medpath.com/news/alx-oncology-announces-results-from-phase-1b-2-trial-of-evorpacept-in-combination-with 2024-11-01T21:54:19+00:00 weekly 0.7 https://trial.medpath.com/news/cmn-weekly-1-november-2024-your-weekly-crispr-medicine-news 2024-11-01T21:36:55+00:00 weekly 0.7 https://trial.medpath.com/news/a-sickle-cell-cure-exists-but-patients-need-more-than-just-gene-therapy-pharmavoice 2024-11-01T21:33:49+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-formally-submits-bla-for-subcutaneous-autoinjector-of-lecanemab-neurologylive 2024-11-01T21:33:34+00:00 weekly 0.7 https://trial.medpath.com/news/ameluz-pdt-leads-to-target-lesion-clearance-in-superficial-basal-cell-carcinoma 2024-11-01T21:28:34+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-ai-tool-that-flags-signs-of-heart-disease-in-chest-ct-scans 2024-11-01T21:23:56+00:00 weekly 0.7 https://trial.medpath.com/news/novo-s-wegovy-comparable-to-madrigal-s-rezdiffra-in-phase-iii-mash-trial-analysts 2024-11-01T21:10:42+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-inc-vir-q3-2024-earnings-call-highlights-st-gurufocus 2024-11-01T21:08:10+00:00 weekly 0.7 https://trial.medpath.com/news/does-an-additional-first-line-option-alter-approach-in-egfr-mutant-nsclc 2024-11-01T20:46:28+00:00 weekly 0.7 https://trial.medpath.com/news/glaucoma-drug-shows-promise-in-targeting-tau-buildup-inside-precision-medicine 2024-11-01T20:25:42+00:00 weekly 0.7 https://trial.medpath.com/news/eliminate-trial-uuti-regimen-demonstrates-initial-tolerability-efficacy-urology-times 2024-11-01T20:20:48+00:00 weekly 0.7 https://trial.medpath.com/news/fda-panel-rejects-lexicon-s-zynquista-for-type-1-diabetes-benzinga 2024-11-01T20:09:40+00:00 weekly 0.7 https://trial.medpath.com/news/feliqs-receives-u-s-fda-fast-track-designation-for-flq-101-a-first-in-class-small-biospace 2024-11-01T20:00:02+00:00 weekly 0.7 https://trial.medpath.com/news/earnings-call-compass-pathways-reports-q3-results-and-trial-updates-investing-com 2024-11-01T19:26:45+00:00 weekly 0.7 https://trial.medpath.com/news/nvo-reports-positive-phase-iii-trial-results-for-semaglutide-in-mash-treatment 2024-11-01T19:25:17+00:00 weekly 0.7 https://trial.medpath.com/news/teva-presents-latest-schizophrenia-treatment-research-including-phase-3-solaris-trial 2024-11-01T19:23:15+00:00 weekly 0.7 https://trial.medpath.com/news/casdatifan-demonstrates-durable-activity-in-metastatic-clear-cell-renal-cell-carcinoma 2024-11-01T19:18:19+00:00 weekly 0.7 https://trial.medpath.com/news/fda-s-october-2024-highlights-advancing-treatments-in-oncology 2024-11-01T19:17:33+00:00 weekly 0.7 https://trial.medpath.com/news/oncology-drugs-approved-by-the-fda-in-october-2024-cure-today 2024-11-01T19:13:29+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-a-s-semaglutide-2-4-mg-demonstrates-superior-globenewswire 2024-11-01T18:51:02+00:00 weekly 0.7 https://trial.medpath.com/news/two-topical-treatments-show-similar-benefits-for-photoaging-of-the-hands-news-medical 2024-11-01T18:38:00+00:00 weekly 0.7 https://trial.medpath.com/news/stelara-may-be-effective-for-type-1-diabetes-in-adolescents 2024-11-01T18:06:08+00:00 weekly 0.7 https://trial.medpath.com/news/essa-pharma-halts-phase-ii-study-of-masofaniten-in-prostate-cancer-treatment 2024-11-01T18:00:25+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-completes-rolling-biologics-license-application-to-fda-for-subcutaneous 2024-11-01T17:53:17+00:00 weekly 0.7 https://trial.medpath.com/news/lexicon-loses-fda-adcomm-vote-on-insulin-adjunct-for-patients-with-type-1-diabetes 2024-11-01T17:40:32+00:00 weekly 0.7 https://trial.medpath.com/news/phase-iii-trials-show-long-term-efficacy-of-cobenfy-treating-schizophrenia 2024-11-01T17:36:59+00:00 weekly 0.7 https://trial.medpath.com/news/anti-tau-antibody-stumbles-in-phase-ii-alzheimer-trial-nature 2024-11-01T17:26:30+00:00 weekly 0.7 https://trial.medpath.com/news/ucb-weighs-up-alzheimer-s-drug-future-after-phase-ii-miss-and-roche-exit-scrip 2024-11-01T17:11:11+00:00 weekly 0.7 https://trial.medpath.com/news/the-phase-iii-clinical-trial-application-for-first-line-treatment-of-extensive-disease-small-cell 2024-11-01T17:05:47+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-completes-rolling-submission-to-us-fda-for-leqembi-r-lecanemab-irmb-biologics 2024-11-01T17:05:06+00:00 weekly 0.7 https://trial.medpath.com/news/tizona-s-ttx-080-colorectal-cancer-trial-expands-with-new-arms 2024-11-01T17:00:23+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-scemblix-for-newly-diagnosed-cml-patients-the-cancer-letter 2024-11-01T16:51:12+00:00 weekly 0.7 https://trial.medpath.com/news/phase-2-trial-of-masofaniten-plus-enzalutamide-in-mcrpc-has-been-terminated 2024-11-01T16:51:09+00:00 weekly 0.7 https://trial.medpath.com/news/high-grade-cesium-results-continue-in-latest-drilling-phase-nationtalk 2024-11-01T16:44:07+00:00 weekly 0.7 https://trial.medpath.com/news/novo-with-new-results-to-seek-approval-for-obesity-drug-in-mash-biopharma-dive 2024-11-01T16:40:21+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-red-tape-and-ethics-under-the-microscope-research-professional-news 2024-11-01T16:36:01+00:00 weekly 0.7 https://trial.medpath.com/news/recce-pharmaceuticals-reports-solid-progress-in-clinical-trials-raises-a-12-5-million-in 2024-11-01T16:33:42+00:00 weekly 0.7 https://trial.medpath.com/news/predicting-pathological-response-of-neoadjuvant-conversion-therapy-for-jhc-dove-medical-press 2024-11-01T16:31:00+00:00 weekly 0.7 https://trial.medpath.com/news/powering-a-new-paradigm-for-pathology-danaher 2024-11-01T16:23:51+00:00 weekly 0.7 https://trial.medpath.com/news/a-narrative-review-focusing-on-randomized-clinical-trials-rcts-of-vitamin-d-frontiers 2024-11-01T16:21:39+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-t1d-expresses-disappointment-in-fda-advisory-committee 2024-11-01T15:54:42+00:00 weekly 0.7 https://trial.medpath.com/news/treatments-in-clinical-trials-for-small-cell-lung-cancer-healthline 2024-11-01T15:44:51+00:00 weekly 0.7 https://trial.medpath.com/news/us-court-upholds-avadel-s-narcolepsy-drug-approval-amid-exclusivity-battle 2024-11-01T15:44:49+00:00 weekly 0.7 https://trial.medpath.com/news/taking-on-acquired-resistance-in-egfr-mutant-nsclc-medpage-today 2024-11-01T15:35:14+00:00 weekly 0.7 https://trial.medpath.com/news/year-in-review-non-small-cell-lung-cancer-medpage-today 2024-11-01T15:35:12+00:00 weekly 0.7 https://trial.medpath.com/news/insomnia-breakthrough-handheld-device-in-development-may-soon-zap-away-sleepless-nights 2024-11-01T15:22:34+00:00 weekly 0.7 https://trial.medpath.com/news/envoy-medical-receives-fda-approval-to-initiate-pivotal-globenewswire 2024-11-01T15:19:44+00:00 weekly 0.7 https://trial.medpath.com/news/inotuzumab-ozogamicin-with-low-intensity-chemotherapy-in-older-patients-with-cd22 2024-11-01T15:11:55+00:00 weekly 0.7 https://trial.medpath.com/news/online-yoga-classes-can-ease-lower-back-pain 2024-11-01T15:11:43+00:00 weekly 0.7 https://trial.medpath.com/news/earnings-call-vir-biotechnology-advances-with-sanofi-deal-hepatitis-trials-investing-com 2024-11-01T15:11:41+00:00 weekly 0.7 https://trial.medpath.com/news/chemo-should-be-tailored-to-decrease-neuropathy-in-black-patients-oncology-nursing-news 2024-11-01T15:08:37+00:00 weekly 0.7 https://trial.medpath.com/news/effectiveness-of-virtual-yoga-for-chronic-low-back-pain-a-randomized-clinical-trial 2024-11-01T15:03:14+00:00 weekly 0.7 https://trial.medpath.com/news/fda-roundup-agency-highlights-from-october-2024-drug-topics 2024-11-01T14:45:42+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-hympavzi-for-hemophilia-a-and-b-treatment-technology-networks 2024-11-01T14:41:13+00:00 weekly 0.7 https://trial.medpath.com/news/regeneron-battles-wall-street-uncertainty-madrigal-extends-fast-launch-of-mash-drug 2024-11-01T14:40:42+00:00 weekly 0.7 https://trial.medpath.com/news/obesity-is-the-new-hypertension-the-current-landscape-of-pharmacological-weight-loss 2024-11-01T14:31:08+00:00 weekly 0.7 https://trial.medpath.com/news/video-experts-consider-endpoints-for-clinical-trials-in-geographic-atrophy-healio 2024-11-01T14:31:01+00:00 weekly 0.7 https://trial.medpath.com/news/uk-approves-cstone-s-sugemalimab-for-non-small-cell-lung-cancer-treatment 2024-11-01T14:11:53+00:00 weekly 0.7 https://trial.medpath.com/news/madrigal-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides 2024-11-01T14:08:11+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-biogen-eye-2025-approval-for-leqembi-autoinjector-pharmaphorum 2024-11-01T14:07:17+00:00 weekly 0.7 https://trial.medpath.com/news/hansoh-pharmaceutical-group-company-limited-announces-the-nmpa-has-granted 2024-11-01T14:02:08+00:00 weekly 0.7 https://trial.medpath.com/news/overcollection-of-data-adds-months-to-clinical-trials-and-reduces-roi-finds-new-phesi-analysis 2024-11-01T13:58:12+00:00 weekly 0.7 https://trial.medpath.com/news/pl-developments-receives-fda-approval-for-over-the-counter-omeprazole 2024-11-01T13:36:37+00:00 weekly 0.7 https://trial.medpath.com/news/earnings-call-insmed-reports-strong-q3-growth-eyes-brensocatib-launch-investing-com 2024-11-01T13:31:30+00:00 weekly 0.7 https://trial.medpath.com/news/with-new-wegovy-data-in-hand-novo-nordisk-will-file-for-approval-in-mash-stat-news 2024-11-01T13:24:12+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-can-new-blood-tests-help-diagnose-the-disease-early-medicalnewstoday 2024-11-01T13:07:17+00:00 weekly 0.7 https://trial.medpath.com/news/readout-newsletter-madrigal-eli-lilly-compass-pathways-latest-stat-news 2024-11-01T13:03:19+00:00 weekly 0.7 https://trial.medpath.com/news/break-through-cancer-announces-first-patient-enrolled-in-phase-2-trial-targeting-residual 2024-11-01T12:58:53+00:00 weekly 0.7 https://trial.medpath.com/news/biofrontera-stock-climbs-as-drug-device-succeeds-in-phase-iii-skin-cancer-trial 2024-11-01T12:43:03+00:00 weekly 0.7 https://trial.medpath.com/news/disparities-in-ibs-clinical-trial-participation-suggest-healthcare-research-inequities 2024-11-01T12:40:51+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-medtech-concludes-enrolment-for-omny-af-trial-pilot-phase 2024-11-01T12:38:09+00:00 weekly 0.7 https://trial.medpath.com/news/sotagliflozin-setback-cautionary-fda-adcomm-vote-reflects-continued-concern-for 2024-11-01T12:38:03+00:00 weekly 0.7 https://trial.medpath.com/news/dijon-biotech-company-inventiva-raises-348-million-to-complete-its-phase-iii-born2invest 2024-11-01T12:35:27+00:00 weekly 0.7 https://trial.medpath.com/news/corcept-s-relacorilant-gradient-trial-misses-primary-endpoint 2024-11-01T12:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/roche-weighs-whether-speedy-approval-path-is-open-for-latest-alzheimer-s-drug 2024-11-01T12:27:13+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-scemblix-granted-fda-accelerated-approval-in-newly-diagnosed-cml-pmlive 2024-11-01T12:26:58+00:00 weekly 0.7 https://trial.medpath.com/news/dermavant-reports-positive-long-term-results-for-vtama-cream-in-atopic-dermatitis-pmlive 2024-11-01T12:22:54+00:00 weekly 0.7 https://trial.medpath.com/news/envoy-medical-receives-fda-approval-to-initiate-pivotal-clinical-study-for-breakthrough 2024-11-01T12:14:32+00:00 weekly 0.7 https://trial.medpath.com/news/sutro-biopharma-announces-initiation-of-the-registration-enabling-reframe-p1-trial-with 2024-11-01T12:14:30+00:00 weekly 0.7 https://trial.medpath.com/news/envoy-medical-receives-fda-approval-to-initiate-pivotal-clinical-study-for-breakthrough 2024-11-01T12:09:53+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-completes-rolling-submission-to-us-fda-for-leqembi-r-lecanemab-irmb-biologics 2024-11-01T12:08:21+00:00 weekly 0.7 https://trial.medpath.com/news/mechanisms-of-acquired-resistance-in-first-line-treatment-amivantamab-plus-lazertinib 2024-11-01T12:01:13+00:00 weekly 0.7 https://trial.medpath.com/news/biofrontera-stock-climbs-as-drug-device-succeeds-in-phase-iii-skin-cancer-trial 2024-11-01T12:00:26+00:00 weekly 0.7 https://trial.medpath.com/news/seltorexant-shows-promise-as-first-in-class-treatment-for-depression-with-insomnia-in-phase-iii-trial 2024-11-01T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/merck-and-moderna-initiate-phase-3-trial-evaluating-adjuvant-v940-in-combination-with-keytruda 2024-11-01T11:44:59+00:00 weekly 0.7 https://trial.medpath.com/news/earnings-call-galapagos-reports-solid-q3-progress-eyes-ind-studies-investing-com 2024-11-01T11:31:42+00:00 weekly 0.7 https://trial.medpath.com/news/the-phase-iii-clinical-trial-application-for-first-line-treatment-of-extensive-disease-small-cell 2024-11-01T11:30:52+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-treatment-of-arteriovenous-malformation-shine-news-shanghai-daily 2024-11-01T11:27:15+00:00 weekly 0.7 https://trial.medpath.com/news/ondine-raising-ps8-5m-to-fund-us-clinical-trial-sharecast-com 2024-11-01T11:26:52+00:00 weekly 0.7 https://trial.medpath.com/news/memo-therapeutics-ag-announces-last-patient-enrolled-in-globenewswire 2024-11-01T11:18:08+00:00 weekly 0.7 https://trial.medpath.com/news/aim-vaccine-co-ltd-announces-13-valent-pneumonia-conjugate-vaccine-marketscreener 2024-11-01T11:16:50+00:00 weekly 0.7 https://trial.medpath.com/news/memo-therapeutics-ag-announces-last-patient-enrolled-in-phase-ii-clinical-trial-of-morningstar 2024-11-01T11:12:08+00:00 weekly 0.7 https://trial.medpath.com/news/diadem-unveils-novel-findings-on-early-alzheimer-s-disease-detection-using-p53-specific-antibody-at-ctad-2024 2024-11-01T11:11:02+00:00 weekly 0.7 https://trial.medpath.com/news/memo-therapeutics-ag-announces-last-patient-enrolled-in-phase-ii-clinical-trial-of 2024-11-01T11:07:06+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-revised-implementing-regulations-of-the-human-research-act-swissmedic 2024-11-01T10:39:18+00:00 weekly 0.7 https://trial.medpath.com/news/lexicon-s-type-1-diabetes-drug-voted-down-by-fda-adcomm-pharmaphorum 2024-11-01T10:27:26+00:00 weekly 0.7 https://trial.medpath.com/news/no-evidence-adults-with-autism-are-more-vulnerable-to-criminals-study-finds 2024-11-01T10:11:22+00:00 weekly 0.7 https://trial.medpath.com/news/ozempic-wegovy-could-help-ease-knee-arthritis-pain 2024-11-01T10:11:01+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-hympavzi-for-hemophilia-a-and-b-treatment-technology-networks 2024-11-01T10:07:36+00:00 weekly 0.7 https://trial.medpath.com/news/hansoh-pharma-s-breakthrough-in-cancer-drug-development-tipranks-com 2024-11-01T09:37:31+00:00 weekly 0.7 https://trial.medpath.com/news/8th-summit-advances-antigen-specific-immune-tolerance-therapies-for-autoimmune-diseases 2024-11-01T09:25:33+00:00 weekly 0.7 https://trial.medpath.com/news/fda-adcomm-votes-against-lexicon-type-1-diabetes-and-ckd-drug-endpoints-news 2024-11-01T09:11:03+00:00 weekly 0.7 https://trial.medpath.com/news/reductions-in-substance-use-as-outcome-targets-for-treatment-development 2024-11-01T08:51:18+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-biogen-eye-2025-approval-for-subcutaneous-leqembi-pharmaphorum 2024-11-01T08:02:01+00:00 weekly 0.7 https://trial.medpath.com/news/new-trials-for-potential-flu-and-norovirus-vaccines-dartmouth-today-co-uk 2024-11-01T08:00:45+00:00 weekly 0.7 https://trial.medpath.com/news/blue-therapeutics-gets-financing-to-push-radiotherapies-european-biotechnology 2024-11-01T07:48:30+00:00 weekly 0.7 https://trial.medpath.com/news/recruiting-and-retaining-healthcare-workers-in-scotland-to-a-longitudinal-covid-19-study 2024-11-01T07:29:37+00:00 weekly 0.7 https://trial.medpath.com/news/incorporating-external-controls-in-the-design-of-randomized-clinical-trials-a-case-study-in-solid-tumors 2024-11-01T07:29:35+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-completes-rolling-submission-to-us-fda-for-leqembi-r-lecanemab-irmb-biologics 2024-11-01T07:21:38+00:00 weekly 0.7 https://trial.medpath.com/news/lexicon-announces-outcome-of-fda-advisory-committee-for-zynquistatm-sotagliflozin-as 2024-11-01T07:21:38+00:00 weekly 0.7 https://trial.medpath.com/news/intensity-therapeutics-inc-and-the-swiss-group-for-clinical-cancer-research-sakk-biospace 2024-11-01T07:21:38+00:00 weekly 0.7 https://trial.medpath.com/news/akeso-announces-first-patient-enrollment-in-phase-3-trial-of-ivonescimab-combination-as 2024-11-01T07:21:37+00:00 weekly 0.7 https://trial.medpath.com/news/regeneron-reports-third-quarter-2024-financial-and-operating-results-biospace 2024-11-01T07:21:29+00:00 weekly 0.7 https://trial.medpath.com/news/h-lundbeck-a-s-announces-positive-results-from-phase-iii-pivotal-trial-of-vyepti 2024-11-01T07:20:36+00:00 weekly 0.7 https://trial.medpath.com/news/opdivo-and-yervoy-may-improve-survival-for-resected-stage-3-4-melanoma-cure-today 2024-11-01T07:12:42+00:00 weekly 0.7 https://trial.medpath.com/news/alnylam-pharmaceuticals-inc-alny-q3-2024-earnings-highlights 2024-11-01T07:05:20+00:00 weekly 0.7 https://trial.medpath.com/news/agios-pharmaceuticals-inc-agio-q3-2024-earnings-call-highlights-strong-cash-position-and 2024-11-01T07:04:32+00:00 weekly 0.7 https://trial.medpath.com/news/rosella-trial-of-relacorilant-targets-stress-response-to-overcome-chemoresistance-in 2024-11-01T06:59:03+00:00 weekly 0.7 https://trial.medpath.com/news/ai-in-clinical-trials-industry-leaders-call-for-balanced-approach-to-ethics-and-regulation 2024-11-01T06:03:32+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-completes-rolling-submission-to-us-fda-for-leqembi-r-lecanemab-acn-newswire 2024-11-01T05:56:35+00:00 weekly 0.7 https://trial.medpath.com/news/dr-kotecha-on-the-fda-approval-of-optune-lua-in-metastatic-nsclc-onclive 2024-11-01T05:47:03+00:00 weekly 0.7 https://trial.medpath.com/news/akeso-announces-first-patient-enrollment-in-phase-3-trial-of-ivonescimab-combination-as 2024-11-01T05:43:08+00:00 weekly 0.7 https://trial.medpath.com/news/ucb-presents-encouraging-data-on-bepranemab-in-early-alzheimer-s-disease-in-phase-2a 2024-11-01T05:03:13+00:00 weekly 0.7 https://trial.medpath.com/news/critical-drug-shortages-persist-in-us-adhd-medications-chemotherapy-drugs-and-insulin-among-most-affected 2024-11-01T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/verastem-oncology-completes-rolling-nda-submission-to-the-fda-for-avutometinib-biospace 2024-11-01T04:48:07+00:00 weekly 0.7 https://trial.medpath.com/news/study-cholinesterase-inhibitors-show-promise-for-lewy-body-dementia-being-patient 2024-11-01T04:38:43+00:00 weekly 0.7 https://trial.medpath.com/news/handok-s-rare-blood-disorder-treatment-empaveli-wins-insurance-coverage-kbr 2024-11-01T04:26:27+00:00 weekly 0.7 https://trial.medpath.com/news/dimerix-collaborates-with-neptune-for-trial-recruitment-markets-insider 2024-11-01T02:54:18+00:00 weekly 0.7 https://trial.medpath.com/news/akeso-announces-first-patient-enrollment-in-phase-3-trial-of-ivonescimab-combination-as 2024-11-01T02:46:01+00:00 weekly 0.7 https://trial.medpath.com/news/first-fda-approved-treatment-to-delay-type-1-diabetes-ucsf-diabetes-center-57b993 2024-11-01T02:36:04+00:00 weekly 0.7 https://trial.medpath.com/news/lexicon-announces-outcome-of-fda-advisory-committee-for-zynquistatm-sotagliflozin-as 2024-11-01T02:25:13+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-exactech-porous-3d-tibial-implant-for-knee-replacement-massdevice 2024-11-01T02:22:10+00:00 weekly 0.7 https://trial.medpath.com/news/glaucoma-drug-may-pave-unexpected-road-to-a-dementia-cure-study-finds 2024-11-01T02:06:57+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-01T01:52:46+00:00 weekly 0.7 https://trial.medpath.com/news/new-fda-approved-treatment-for-hyperhidrosis-slucare-health-watch-826020 2024-11-01T01:25:01+00:00 weekly 0.7 https://trial.medpath.com/news/essa-pharma-announces-termination-of-phase-2-study-evaluating-masofaniten-combined 2024-11-01T01:17:08+00:00 weekly 0.7 https://trial.medpath.com/news/prolong-pharmaceuticals-gains-us-fda-fast-track-designation-for-novel-stroke-therapy 2024-11-01T00:41:25+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-whets-investors-appetites-for-maritide-obesity-data-by-end-of-year-biospace 2024-11-01T00:38:59+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-completes-rolling-submission-to-us-fda-for-leqembi-r-lecanemab-irmb-biologics 2024-11-01T00:17:07+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-completes-rolling-submission-to-us-fda-for-leqembi-r-lecanemab-irmb-biologics 2024-11-01T00:03:57+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-elevar-s-resubmitted-rivoceranib-and-camrelizumab 2024-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tct-2024-one-year-data-from-sirona-trial-show-similar-results-for 2024-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/primary-day-28-analysis-of-a-phase-2-3-open-label-study 2024-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/immunochemotherapy-shows-promise-for-borderline-resectable-esophageal-cancer-conversion-surgery 2024-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/elexacaftor-tezacaftor-ivacaftor-shows-promise-for-cystic-fibrosis-patients-without-f508del-cftr-variant 2024-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-evaluates-recurrence-of-disease-activity-after-ocrelizumab-discontinuation-in-ms-patients 2024-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-completes-rolling-bla-submission-for-subcutaneous-maintenance-dosing-of-leqembi 2024-10-31T23:51:49+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-completes-rolling-bla-submission-for-subcutaneous-maintenance-dosing-of-leqembi 2024-10-31T23:47:03+00:00 weekly 0.7 https://trial.medpath.com/news/lexicon-pharmaceuticals-gets-negative-fda-panel-vote-for-zynquista-update 2024-10-31T23:34:29+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-reports-third-quarter-2024-financial-results-and-provides-corporate 2024-10-31T23:18:55+00:00 weekly 0.7 https://trial.medpath.com/news/lexicon-announces-outcome-of-fda-advisory-committee-for-globenewswire 2024-10-31T22:59:03+00:00 weekly 0.7 https://trial.medpath.com/news/scs-aua-2024-indications-and-outcomes-for-radiation-therapy-in-renal-masses 2024-10-31T22:41:29+00:00 weekly 0.7 https://trial.medpath.com/news/multicenter-group-compares-real-world-mesothelioma-outcomes-to-clinical-study 2024-10-31T22:33:17+00:00 weekly 0.7 https://trial.medpath.com/news/edwards-medtronic-and-inari-share-trial-data-at-tct-conference-medtech-dive 2024-10-31T22:29:51+00:00 weekly 0.7 https://trial.medpath.com/news/tyra-300-shows-encouraging-safety-efficacy-in-fgfr3-metastatic-urothelial-carcinoma 2024-10-31T22:04:26+00:00 weekly 0.7 https://trial.medpath.com/news/sugemalimab-plus-chemotherapy-earns-uk-approval-in-first-line-metastatic-nsclc 2024-10-31T21:49:24+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-trial-retraining-immune-cells-offers-new-hope-for-patients-in-personalized-medicine 2024-10-31T21:47:45+00:00 weekly 0.7 https://trial.medpath.com/news/the-changing-landscape-of-ph-positive-all-targeted-oncology 2024-10-31T21:47:05+00:00 weekly 0.7 https://trial.medpath.com/news/roche-s-antibody-against-alzheimer-s-looks-the-best-yet-barron-s 2024-10-31T21:36:18+00:00 weekly 0.7 https://trial.medpath.com/news/clindamycin-and-bacterial-load-reduction-as-prophylaxis-for-surgical-site-infection-racgp 2024-10-31T21:21:52+00:00 weekly 0.7 https://trial.medpath.com/news/dermatology-times-october-2024-recap 2024-10-31T21:15:46+00:00 weekly 0.7 https://trial.medpath.com/news/lexicon-announces-outcome-of-fda-advisory-committee-for-zynquista-sotagliflozin-as-an-adjunct-to-insulin-therapy-for-glycemic-control-in-adults-with-type-1-diabetes-and-chronic-kidney-disease 2024-10-31T21:10:39+00:00 weekly 0.7 https://trial.medpath.com/news/nih-trial-of-rectal-microbicide-for-hiv-prevention-begins-in-the-united-states 2024-10-31T21:01:23+00:00 weekly 0.7 https://trial.medpath.com/news/dr-pabon-on-the-fda-approval-of-zolbetuximab-for-cldn18-2-gastric-gej-adenocarcinoma 2024-10-31T20:52:56+00:00 weekly 0.7 https://trial.medpath.com/news/dr-foss-on-the-fda-approval-of-denileukin-diftitox-for-ctcl-onclive 2024-10-31T20:52:56+00:00 weekly 0.7 https://trial.medpath.com/news/abeona-therapeutics-resubmits-bla-to-fda-for-epidermolysis-bullosa-gene-therapy-pz-cel 2024-10-31T20:48:42+00:00 weekly 0.7 https://trial.medpath.com/news/jefferies-raises-kymera-therapeutics-target-to-59-on-immunology-and-inflammation-focus 2024-10-31T20:35:23+00:00 weekly 0.7 https://trial.medpath.com/news/inmune-bio-inc-sec-10-q-report-tradingview 2024-10-31T20:25:59+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-10-31T20:17:13+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-continues-to-fill-its-malaria-pipeline-with-a-long-half-life-iv-compound-for-severe-malaria 2024-10-31T20:16:25+00:00 weekly 0.7 https://trial.medpath.com/news/inmune-bio-inc-announces-third-quarter-2024-results-and-provides-business-update 2024-10-31T20:11:52+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-10-31T20:10:26+00:00 weekly 0.7 https://trial.medpath.com/news/inavolisib-regimen-approval-opens-the-door-for-triplet-therapies-in-hr-her2-breast-cancer 2024-10-31T20:08:18+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-s-wainzua-gains-another-approval-in-england-and-wales-pharmtech 2024-10-31T20:07:25+00:00 weekly 0.7 https://trial.medpath.com/news/iovance-biotherapeutics-to-host-third-quarter-and-globenewswire 2024-10-31T20:04:33+00:00 weekly 0.7 https://trial.medpath.com/news/lecanemab-data-presented-at-ctad-on-early-initiation-and-long-term-treatment-suggest 2024-10-31T19:50:58+00:00 weekly 0.7 https://trial.medpath.com/news/st-luke-s-surgeon-honored-for-research-work-lvb-lehigh-valley-business 2024-10-31T19:50:50+00:00 weekly 0.7 https://trial.medpath.com/news/roche-announces-phase-iii-inavo120-results-were-published-markets-insider 2024-10-31T19:45:26+00:00 weekly 0.7 https://trial.medpath.com/news/exactech-announces-fda-clearance-of-truliant-r-porous-3d-tibial-implant-for-knee 2024-10-31T19:39:17+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-earns-higher-revenues-in-q3-2024-puts-rare-diseases-in-the-spotlight 2024-10-31T19:35:29+00:00 weekly 0.7 https://trial.medpath.com/news/karyopharm-announces-favorable-change-in-co-primary-endpoint-for-pivotal-phase-3 2024-10-31T19:22:54+00:00 weekly 0.7 https://trial.medpath.com/news/a-promising-schizophrenia-drug-showed-mixed-results-what-does-that-mean-for-patients 2024-10-31T19:18:27+00:00 weekly 0.7 https://trial.medpath.com/news/madrigal-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides 2024-10-31T19:17:56+00:00 weekly 0.7 https://trial.medpath.com/news/starget-pharma-secures-5-1m-for-ai-powered-targeted-radiotherapy-for-cancer 2024-10-31T19:16:53+00:00 weekly 0.7 https://trial.medpath.com/news/standout-breast-cancer-trial-outcomes-for-roche-small-molecule-therapy 2024-10-31T19:13:33+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-mcguff-pharmaceuticals-facility-in-santa-ana-ca-contract-pharma 2024-10-31T19:03:39+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-mcguff-pharmaceuticals-facility-in-santa-ana-ca-contract-pharma 2024-10-31T19:02:40+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-mcguff-pharmaceuticals-facility-in-santa-ana-ca-contract-pharma 2024-10-31T19:01:53+00:00 weekly 0.7 https://trial.medpath.com/news/the-role-of-pd-l1-in-patients-with-non-small-cell-lung-cancer-receiving-neoadjuvant-immune 2024-10-31T18:37:49+00:00 weekly 0.7 https://trial.medpath.com/news/new-phase-3-data-suggest-benefits-of-early-lecanemab-initiation-on-alzheimer-disease 2024-10-31T18:28:23+00:00 weekly 0.7 https://trial.medpath.com/news/power-metals-high-grade-cesium-results-continue-in-latest-drilling-phase-junior-mining-network 2024-10-31T18:05:41+00:00 weekly 0.7 https://trial.medpath.com/news/genetic-test-predicts-survival-benefit-from-docetaxel-in-prostate-cancer-oncology-times 2024-10-31T17:46:16+00:00 weekly 0.7 https://trial.medpath.com/news/ninth-circuit-confirms-certain-stem-cell-products-require-fda-premarket-approval 2024-10-31T17:40:57+00:00 weekly 0.7 https://trial.medpath.com/news/oral-and017-granted-orphan-drug-status-for-scd-sickle-cell-disease-news 2024-10-31T17:31:19+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-shows-thrombectomy-does-not-improve-outcomes-for-patients-with-large-strokes 2024-10-31T17:26:04+00:00 weekly 0.7 https://trial.medpath.com/news/participant-motivations-key-to-success-in-clinical-trials-dermatology-times 2024-10-31T17:10:40+00:00 weekly 0.7 https://trial.medpath.com/news/jancelewicz-co-principal-investigator-on-11-4-million-clinical-trial-grant-to-study 2024-10-31T17:00:07+00:00 weekly 0.7 https://trial.medpath.com/news/defining-the-characteristics-of-breakthrough-invasive-fungal-infections-in-hematologic-disorders 2024-10-31T16:56:24+00:00 weekly 0.7 https://trial.medpath.com/news/alvotech-and-teva-announce-fda-approval-of-additional-presentation-for-ustekinumab-biosimilar 2024-10-31T16:47:18+00:00 weekly 0.7 https://trial.medpath.com/news/madrigal-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides 2024-10-31T16:46:55+00:00 weekly 0.7 https://trial.medpath.com/news/fda-fast-tracks-asciminib-for-new-chronic-leukemia-patients-webmd 2024-10-31T16:46:39+00:00 weekly 0.7 https://trial.medpath.com/news/exactech-announces-fda-clearance-of-truliant-r-porous-3d-tibial-implant-for-knee 2024-10-31T16:37:37+00:00 weekly 0.7 https://trial.medpath.com/news/cell-therapy-weekly-support-for-commercialization-of-complex-therapies-regmednet 2024-10-31T16:37:08+00:00 weekly 0.7 https://trial.medpath.com/news/potentially-transformative-new-breast-cancer-drug-could-stop-disease-in-its-tracks-irish-star 2024-10-31T16:20:34+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-presents-latest-clinical-findings-suggesting-inhibition-of-tau-propagation-by-anti 2024-10-31T16:19:35+00:00 weekly 0.7 https://trial.medpath.com/news/vitamin-k2-reduces-dreaded-nighttime-leg-cramps-in-clinical-trial-medical-xpress 2024-10-31T16:14:04+00:00 weekly 0.7 https://trial.medpath.com/news/court-upholds-fda-approval-of-avadel-s-narcolepsy-drug-lumryz-investing-com 2024-10-31T16:09:42+00:00 weekly 0.7 https://trial.medpath.com/news/sacituzumab-tirumotecan-nda-for-pretreated-egfr-nsclc-accepted-for-review-in-china 2024-10-31T16:08:56+00:00 weekly 0.7 https://trial.medpath.com/news/adjuvant-nivolumab-in-high-risk-muscle-invasive-urothelial-carcinoma-the-asco-post 2024-10-31T16:05:44+00:00 weekly 0.7 https://trial.medpath.com/news/crispr-strategy-could-restore-delayed-onset-hearing-loss-drug-discovery-news 2024-10-31T16:04:00+00:00 weekly 0.7 https://trial.medpath.com/news/hope-biosciences-research-foundation-reports-promising-phase-ii-trial-results-for-stem 2024-10-31T15:54:21+00:00 weekly 0.7 https://trial.medpath.com/news/powerful-new-therapy-doubles-progression-free-survival-in-advanced-breast-cancer-clinical-trial-finds 2024-10-31T15:44:52+00:00 weekly 0.7 https://trial.medpath.com/news/sinaptica-s-neuromodulation-device-aces-phase-ii-alzheimer-s-trial-clinical-trials-arena 2024-10-31T15:36:13+00:00 weekly 0.7 https://trial.medpath.com/news/hope-biosciences-research-foundation-reports-promising-phase-ii-trial-results-for-stem 2024-10-31T15:36:11+00:00 weekly 0.7 https://trial.medpath.com/news/crispr-cas13bt3-silences-vegfa-in-retinal-cells 2024-10-31T15:26:15+00:00 weekly 0.7 https://trial.medpath.com/news/biogen-down-as-morgan-stanley-cuts-rating-on-sluggish-alzheimer-s-drug-launch 2024-10-31T15:23:49+00:00 weekly 0.7 https://trial.medpath.com/news/evommune-raises-115m-to-accelerate-immune-drug-tests-biopharma-dive 2024-10-31T15:14:53+00:00 weekly 0.7 https://trial.medpath.com/news/ovarian-cancer-produces-il-4-to-resist-immunotherapy-inside-precision-medicine 2024-10-31T15:12:29+00:00 weekly 0.7 https://trial.medpath.com/news/nda-submitted-for-3-month-formulation-of-mesylate-for-advanced-prostate-cancer 2024-10-31T15:09:11+00:00 weekly 0.7 https://trial.medpath.com/news/nda-submitted-for-3-month-formulation-of-mesylate-for-advanced-prostate-cancer 2024-10-31T15:09:11+00:00 weekly 0.7 https://trial.medpath.com/news/tuberculosis-how-close-are-we-to-a-new-vaccine-the-bmj 2024-10-31T15:08:55+00:00 weekly 0.7 https://trial.medpath.com/news/navigating-esr1-mutations-in-hr-positive-breast-cancer-with-dr-wander 2024-10-31T15:08:45+00:00 weekly 0.7 https://trial.medpath.com/news/compass-delays-pivotal-trial-readouts-for-psilocybin-in-depression-lays-off-30-of-staff 2024-10-31T15:05:24+00:00 weekly 0.7 https://trial.medpath.com/news/genomic-screening-of-nyc-newborns-highlights-parent-s-interest-and-useful-findings 2024-10-31T14:53:09+00:00 weekly 0.7 https://trial.medpath.com/news/paclitaxel-or-sirolimus-coated-balloons-used-for-arteriovenous-fistulas-2-pave-2-trials 2024-10-31T14:49:53+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-presents-latest-clinical-findings-suggesting-inhibition-of-tau 2024-10-31T14:43:06+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-presents-data-on-benefits-of-long-term-administration-of-dual-acting-lecanemab-at 2024-10-31T14:43:05+00:00 weekly 0.7 https://trial.medpath.com/news/biofrontera-inc-announces-highly-significant-results-in-phase-3-study-of-ameluz-globenewswire 2024-10-31T14:41:11+00:00 weekly 0.7 https://trial.medpath.com/news/sinaptica-s-neuromodulation-device-aces-phase-ii-alzheimer-s-trial 2024-10-31T14:30:44+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-second-set-of-changes-to-irhythm-zio-at-to-resolve-warning-letter-massdevice 2024-10-31T14:30:05+00:00 weekly 0.7 https://trial.medpath.com/news/shanghai-henlius-biotech-organon-announce-fda-acceptance-of-bla-for-hlx14 2024-10-31T14:29:58+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-interpath-009-trial-of-mrna-4157-plus-pembrolizumab-for-nsclc-begins-recruitment 2024-10-31T14:16:32+00:00 weekly 0.7 https://trial.medpath.com/news/pharmadrug-s-sairiyo-therapeutics-announces-successful-completion-of-stability-study-of 2024-10-31T13:58:12+00:00 weekly 0.7 https://trial.medpath.com/news/ventus-therapeutics-announces-successful-completion-of-phase-1-clinical-trial-of-vent 2024-10-31T13:58:10+00:00 weekly 0.7 https://trial.medpath.com/news/recce-pharmaceuticals-announces-interim-efficacy-data-and-safety-approval-for-phase-ii 2024-10-31T13:58:08+00:00 weekly 0.7 https://trial.medpath.com/news/aditxt-s-target-acquisition-appili-therapeutics-announces-alignment-with-fda-on-biospace 2024-10-31T13:58:03+00:00 weekly 0.7 https://trial.medpath.com/news/capricor-therapeutics-and-the-fda-a-daring-risky-filing-strategy-stat-news 2024-10-31T13:52:54+00:00 weekly 0.7 https://trial.medpath.com/news/advanced-therapies-redefine-survival-for-patients-with-breast-cancer-pharmacy-times 2024-10-31T13:48:11+00:00 weekly 0.7 https://trial.medpath.com/news/nih-study-demonstrates-long-term-benefits-of-weight-loss-surgery-in-young-people 2024-10-31T13:42:51+00:00 weekly 0.7 https://trial.medpath.com/news/the-semaglutide-drought-may-be-ending-stat-news 2024-10-31T13:37:13+00:00 weekly 0.7 https://trial.medpath.com/news/compass-cuts-30-of-staff-as-late-stage-psilocybin-drug-trials-face-new-delays 2024-10-31T13:32:35+00:00 weekly 0.7 https://trial.medpath.com/news/new-breast-cancer-therapy-doubles-progression-free-survival-pf-media 2024-10-31T13:22:02+00:00 weekly 0.7 https://trial.medpath.com/news/study-suggests-earlier-is-better-for-heart-valve-replacement-procedures 2024-10-31T13:10:05+00:00 weekly 0.7 https://trial.medpath.com/news/karyopharm-announces-favorable-change-in-co-primary-endpoint-for-pivotal-phase-3 2024-10-31T13:06:48+00:00 weekly 0.7 https://trial.medpath.com/news/madrigal-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides 2024-10-31T13:05:35+00:00 weekly 0.7 https://trial.medpath.com/news/leo-pharma-continues-to-deliver-double-digit-revenue-growth-backed-by-strong-dermatology-sales 2024-10-31T13:03:25+00:00 weekly 0.7 https://trial.medpath.com/news/naya-biosciences-to-present-translational-insights-to 2024-10-31T13:02:36+00:00 weekly 0.7 https://trial.medpath.com/news/aditxt-s-target-acquisition-appili-therapeutics-announces-alignment-with-fda-on-stock-titan 2024-10-31T12:55:18+00:00 weekly 0.7 https://trial.medpath.com/news/uk-dementia-clinical-trial-participation-set-to-boost-by-tens-of-thousands-pharmatimes 2024-10-31T12:47:04+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-grants-accelerated-approval-to-novartis-scemblix-for-adult-patients-with-newly 2024-10-31T12:29:31+00:00 weekly 0.7 https://trial.medpath.com/news/acumen-pharmaceuticals-presents-innovative-trial-screening-advancements-morningstar 2024-10-31T12:27:47+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-trial-retraining-immune-cells-offers-new-hope-for-patients-in-personalized-medicine 2024-10-31T12:22:14+00:00 weekly 0.7 https://trial.medpath.com/news/anavex-s-blarcamesine-achieves-pre-specified-efficacy-in-phase-iib-iii-alzheimer-s-trial 2024-10-31T12:18:57+00:00 weekly 0.7 https://trial.medpath.com/news/high-grade-cesium-results-continue-in-latest-drilling-phase-canada-newswire 2024-10-31T12:14:26+00:00 weekly 0.7 https://trial.medpath.com/news/alloplex-s-cancer-immunotherapy-shows-promise-in-phase-i-trial 2024-10-31T12:05:39+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-regenerative-medicine-advanced-therapy-designation-to-allo-316-in-cd70 2024-10-31T12:04:12+00:00 weekly 0.7 https://trial.medpath.com/news/medidata-launches-bundled-solutions-to-support-oncology-and-vaccine-trials 2024-10-31T12:03:31+00:00 weekly 0.7 https://trial.medpath.com/news/lundbeck-announces-positive-results-from-phase-iii-pivotal-trial-sunrise-of-vyepti 2024-10-31T11:51:55+00:00 weekly 0.7 https://trial.medpath.com/news/lundbeck-announces-positive-results-from-phase-iii-pivotal-trial-sunrise-of-vyepti-placera 2024-10-31T11:49:02+00:00 weekly 0.7 https://trial.medpath.com/news/madrigal-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides 2024-10-31T11:39:03+00:00 weekly 0.7 https://trial.medpath.com/news/palatin-completes-enrollment-in-phase-2-clinical-study-of-bremelanotide-mc4r-agonist 2024-10-31T11:36:45+00:00 weekly 0.7 https://trial.medpath.com/news/palatin-completes-enrollment-in-phase-2-clinical-study-of-bremelanotide-mc4r-agonist 2024-10-31T11:36:29+00:00 weekly 0.7 https://trial.medpath.com/news/avadel-pharmaceuticals-announces-favorable-ruling-in-administrative-procedure-act-litigation 2024-10-31T11:28:55+00:00 weekly 0.7 https://trial.medpath.com/news/appili-therapeutics-announces-alignment-with-fda-on-globenewswire 2024-10-31T11:19:26+00:00 weekly 0.7 https://trial.medpath.com/news/madrigal-pharmaceuticals-reports-third-quarter-2024-globenewswire 2024-10-31T11:16:28+00:00 weekly 0.7 https://trial.medpath.com/news/breast-cancer-breakthrough-as-new-drug-combination-stops-disease-in-its-tracks 2024-10-31T11:15:10+00:00 weekly 0.7 https://trial.medpath.com/news/avadel-pharmaceuticals-announces-favorable-ruling-in-globenewswire 2024-10-31T11:13:43+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-accelerated-approval-for-leukemia-treatment-becker-s-hospital-review 2024-10-31T11:02:50+00:00 weekly 0.7 https://trial.medpath.com/news/personalized-neuromodulation-treatment-significantly-slowed-alzheimer-s-progression-in 2024-10-31T11:00:22+00:00 weekly 0.7 https://trial.medpath.com/news/syros-pharmaceuticals-inc-sec-10-q-report-tradingview 2024-10-31T10:57:50+00:00 weekly 0.7 https://trial.medpath.com/news/compass-pathways-plc-sec-10-q-report-tradingview 2024-10-31T10:47:52+00:00 weekly 0.7 https://trial.medpath.com/news/curevo-presents-positive-shingles-vaccine-outcomes-data 2024-10-31T10:37:54+00:00 weekly 0.7 https://trial.medpath.com/news/retraining-immune-cells-offers-new-hope-for-patients-in-personalized-medicine-breakthrough 2024-10-31T10:06:49+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-trial-retraining-immune-cells-offers-new-hope-for-patients-in-personalized-medicine 2024-10-31T10:06:43+00:00 weekly 0.7 https://trial.medpath.com/news/first-site-initiated-in-australia-for-mannkind-s-phase-3-clinical-trial-evaluating-clofazimine 2024-10-31T09:48:46+00:00 weekly 0.7 https://trial.medpath.com/news/corcept-therapeutics-announces-third-quarter-financial-results-positive-results-biospace 2024-10-31T09:48:46+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-food-and-drug-administration-fda-grants-prolong-pharmaceuticals-fda-fast-track 2024-10-31T09:48:45+00:00 weekly 0.7 https://trial.medpath.com/news/noema-pharma-announces-first-patients-dosed-in-phase-2b-study-with-gemlapodect-noe 2024-10-31T09:48:44+00:00 weekly 0.7 https://trial.medpath.com/news/t-cell-malignancies-clinical-trial-pipeline-insights-featuring-70-companies-delveinsight 2024-10-31T09:46:47+00:00 weekly 0.7 https://trial.medpath.com/news/jpmorgan-sees-cipla-stock-upside-as-fda-approval-accelerates-gabraxane-launch 2024-10-31T09:16:33+00:00 weekly 0.7 https://trial.medpath.com/news/daiichi-sankyo-astrazeneca-launch-phase-iii-trials-of-datopotamab-deruxtecan-in 2024-10-31T09:06:04+00:00 weekly 0.7 https://trial.medpath.com/news/powerful-new-therapy-doubles-progression-free-survival-in-advanced-breast-cancer 2024-10-31T09:00:58+00:00 weekly 0.7 https://trial.medpath.com/news/a-one-week-elderberry-juice-intervention-augments-the-fecal-microbiota-and-suggests-pubmed 2024-10-31T09:00:23+00:00 weekly 0.7 https://trial.medpath.com/news/protega-pharma-receives-us-fda-approval-for-roxybond-ir-10-mg-tablet-with-abuse 2024-10-31T08:59:56+00:00 weekly 0.7 https://trial.medpath.com/news/anavex-s-blarcamesine-achieves-pre-specified-efficacy-in-phase-iib-iii-alzheimer-s-trial 2024-10-31T08:14:55+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-accelerated-approval-of-scemblix-for-newly-diagnosed-cml 2024-10-31T07:32:39+00:00 weekly 0.7 https://trial.medpath.com/news/biofuture-2024-fda-eases-the-way-for-cell-and-gene-therapy-companies-bioworld 2024-10-31T07:30:53+00:00 weekly 0.7 https://trial.medpath.com/news/abionic-s-capsule-psp-receives-fda-approval-for-early-detection-of-sepsis 2024-10-31T07:10:17+00:00 weekly 0.7 https://trial.medpath.com/news/countdown-to-approval-mesoblast-readies-for-ryoncil-s-fda-milestone-sharecafe 2024-10-31T07:10:17+00:00 weekly 0.7 https://trial.medpath.com/news/inventiva-announces-the-positive-recommendation-of-the-fifth-dmc-of-the-nativ3-phase-3 2024-10-31T06:45:58+00:00 weekly 0.7 https://trial.medpath.com/news/optiscan-doubles-revenue-boosts-profit-for-sep-qtr-brisbane-times 2024-10-31T06:30:26+00:00 weekly 0.7 https://trial.medpath.com/news/chugai-files-for-additional-indication-of-tecentriq-for-the-treatment-of-extranodal-natural 2024-10-31T06:25:49+00:00 weekly 0.7 https://trial.medpath.com/news/takeda-announces-strong-first-half-fy2024-results-and-raises-full-year-outlook 2024-10-31T06:23:44+00:00 weekly 0.7 https://trial.medpath.com/news/new-england-journal-of-medicine-publishes-landmark-phase-iii-results-for-roche-s-itovebi 2024-10-31T06:14:12+00:00 weekly 0.7 https://trial.medpath.com/news/ttvr-with-evoque-device-linked-to-substantial-benefits-after-1-year 2024-10-31T06:13:00+00:00 weekly 0.7 https://trial.medpath.com/news/company-announcement-ft-com-markets-data 2024-10-31T06:11:10+00:00 weekly 0.7 https://trial.medpath.com/news/new-england-journal-of-medicine-publishes-landmark-phase-iii-results-for-roche-s-itovebi 2024-10-31T06:05:26+00:00 weekly 0.7 https://trial.medpath.com/news/new-three-drug-therapy-could-double-breast-cancer-survival-time-yahoo 2024-10-31T05:47:40+00:00 weekly 0.7 https://trial.medpath.com/news/fda-regulations-evolve-as-science-changes-elevar-therapeutics-coo-kbr 2024-10-31T05:07:25+00:00 weekly 0.7 https://trial.medpath.com/news/cstone-announces-mhra-approval-of-sugemalimab-for-first-line-treatment-of-non-small 2024-10-31T05:07:17+00:00 weekly 0.7 https://trial.medpath.com/news/multidisciplinary-teams-transform-stage-3a-lung-cancer-care-with-precision-medicine-approach 2024-10-31T04:58:00+00:00 weekly 0.7 https://trial.medpath.com/news/shuttle-pharma-doses-three-subjects-in-phase-ii-glioblastoma-treatment-trial 2024-10-31T04:55:25+00:00 weekly 0.7 https://trial.medpath.com/news/acurate-ide-trial-misses-primary-endpoint-in-all-risk-tavi-patients-tctmd-com 2024-10-31T04:45:01+00:00 weekly 0.7 https://trial.medpath.com/news/cipla-shares-rise-10-after-usfda-paves-way-for-abraxane-drug-launch-news18 2024-10-31T04:33:10+00:00 weekly 0.7 https://trial.medpath.com/news/ucb-presents-encouraging-data-on-bepranemab-in-early-alzheimers-disease-in-phase-2a-study-at-ctad-2024 2024-10-31T04:11:56+00:00 weekly 0.7 https://trial.medpath.com/news/nih-trial-of-rectal-microbicide-for-hiv-prevention-begins-in-the-united-states 2024-10-31T04:10:13+00:00 weekly 0.7 https://trial.medpath.com/news/new-vaccine-production-process-could-help-in-health-emergencies 2024-10-31T04:01:37+00:00 weekly 0.7 https://trial.medpath.com/news/sichuan-kelun-biotech-s-promising-drug-gains-key-approval-markets-insider 2024-10-31T03:57:40+00:00 weekly 0.7 https://trial.medpath.com/news/abionic-s-capsule-psp-receives-fda-approval-for-early-detection-of-sepsis 2024-10-31T03:57:26+00:00 weekly 0.7 https://trial.medpath.com/news/fda-didn-t-flub-approval-in-orphan-drug-case-dc-court-says-law360-uk 2024-10-31T03:50:19+00:00 weekly 0.7 https://trial.medpath.com/news/acurate-neo2tm-aortic-valve-system-data-presented-at-late-breaking-clinical-trial 2024-10-31T03:43:01+00:00 weekly 0.7 https://trial.medpath.com/news/medable-and-google-cloud-partner-to-revolutionize-digital-clinical-trial-platform-access 2024-10-31T03:36:45+00:00 weekly 0.7 https://trial.medpath.com/news/verastem-oncology-completes-rolling-nda-submission-to-the-fda-for-avutometinib-plus-defactinib-as-a-treatment-for-recurrent-kras-mutant-low-grade-serous-ovarian-cancer 2024-10-31T03:10:54+00:00 weekly 0.7 https://trial.medpath.com/news/2024-ncoda-summit-highlights-advances-in-cancer-care-and-treatment-innovation 2024-10-31T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/l-k-biomed-earns-fda-approval-for-new-lumbar-spine-device 2024-10-31T02:51:40+00:00 weekly 0.7 https://trial.medpath.com/news/abionic-s-capsule-psp-receives-fda-approval-for-early-detection-of-sepsis-morningstar 2024-10-31T02:40:00+00:00 weekly 0.7 https://trial.medpath.com/news/clofutriben-shows-promise-in-trial-for-endogenous-cushing-s-syndrome 2024-10-31T02:37:18+00:00 weekly 0.7 https://trial.medpath.com/news/abionic-s-capsule-psp-receives-fda-approval-for-early-detection-of-sepsis 2024-10-31T02:27:12+00:00 weekly 0.7 https://trial.medpath.com/news/nature-cell-s-jointstem-receives-fda-rmat-designation-hiteunyuseu 2024-10-31T02:22:27+00:00 weekly 0.7 https://trial.medpath.com/news/cutia-therapeutics-announces-trial-success-for-fat-reduction-drug-markets-insider 2024-10-31T02:16:39+00:00 weekly 0.7 https://trial.medpath.com/news/c-o-r-r-e-c-t-i-o-n-akeso-inc-company-announcement-ft-com-markets-data 2024-10-31T01:35:48+00:00 weekly 0.7 https://trial.medpath.com/news/countdown-to-approval-mesoblast-readies-for-ryoncil-s-fda-milestone-finance-news-network 2024-10-31T01:23:39+00:00 weekly 0.7 https://trial.medpath.com/news/advancing-alzheimer-treatment-through-gamma-oscillation-stimulation-ralph-kern-md-mhsc 2024-10-31T01:12:28+00:00 weekly 0.7 https://trial.medpath.com/news/pembrolizumab-plus-chemotherapy-enhances-outcomes-in-early-stage-tnbc 2024-10-31T01:04:05+00:00 weekly 0.7 https://trial.medpath.com/news/it-was-a-revolution-the-forgotten-australian-whose-medical-breakthrough-saved-millions-of-lives 2024-10-31T01:02:48+00:00 weekly 0.7 https://trial.medpath.com/news/akeso-announces-first-patient-enrollment-in-phase-3-trial-of-ivonescimab-combined-with 2024-10-31T00:53:38+00:00 weekly 0.7 https://trial.medpath.com/news/nda-submitted-for-3-month-formulation-of-leuprolide-mesylate-for-advanced-prostate-cancer 2024-10-31T00:37:06+00:00 weekly 0.7 https://trial.medpath.com/news/three-drug-treatment-for-breast-cancer-can-delay-the-spread-of-disease-daily-mail 2024-10-31T00:35:06+00:00 weekly 0.7 https://trial.medpath.com/news/fda-expands-approval-for-shorla-s-jylamvo-for-paediatric-patients 2024-10-31T00:07:04+00:00 weekly 0.7 https://trial.medpath.com/news/triumvira-immunologics-to-present-new-clinical-data-from-ongoing-claudin-18-2-phase-1 2024-10-31T00:01:11+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-presents-data-on-benefits-of-long-term-administration-globenewswire 2024-10-30T23:39:26+00:00 weekly 0.7 https://trial.medpath.com/news/appendix-4c-quarterly-activity-report-for-quarter-ended-september-30-2024-quantisnow 2024-10-30T23:28:28+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-shares-positive-phase-iii-data-of-mirikizumab-for-the-treatment-of-crohn-s-disease 2024-10-30T23:24:37+00:00 weekly 0.7 https://trial.medpath.com/news/appendix-4c-quarterly-activity-report-for-quarter-ended-september-30-2024-globenewswire 2024-10-30T23:13:31+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-secures-first-line-cml-expansion-for-scemblix-projects-3b-in-peak-sales 2024-10-30T23:12:01+00:00 weekly 0.7 https://trial.medpath.com/news/fda-staff-not-quite-sold-on-sotagliflozin-for-t1d-patients-with-ckd-medpage-today 2024-10-30T23:06:57+00:00 weekly 0.7 https://trial.medpath.com/news/new-hope-for-breast-cancer-patients-after-huge-therapy-breakthrough-mirror-online 2024-10-30T22:59:31+00:00 weekly 0.7 https://trial.medpath.com/news/leukemia-drug-shows-promise-in-dementia-with-lewy-bodies-medpage-today 2024-10-30T22:57:42+00:00 weekly 0.7 https://trial.medpath.com/news/three-drug-mix-doubles-survival-time-for-advanced-breast-cancer-the-times 2024-10-30T22:34:11+00:00 weekly 0.7 https://trial.medpath.com/news/karyopharm-to-host-investor-event-with-leading-myelofibrosis-kols-and-provide-a 2024-10-30T22:30:28+00:00 weekly 0.7 https://trial.medpath.com/news/fda-issues-warning-on-biozorb-markers-after-recall-due-to-patient-complications 2024-10-30T22:19:34+00:00 weekly 0.7 https://trial.medpath.com/news/intravesical-mitomycin-demonstrates-significant-duration-of-response-in-nmibc 2024-10-30T22:19:33+00:00 weekly 0.7 https://trial.medpath.com/news/phase-ii-study-of-upar-pet-ct-for-staging-of-primary-breast-cancer-in-comparison-with 2024-10-30T22:08:01+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-trailrunner-alz-3-to-test-effects-of-igg1-monoclonal-antibody-remternetug-in 2024-10-30T22:08:00+00:00 weekly 0.7 https://trial.medpath.com/news/3-to-know-nch-partners-for-clinical-trials-student-dies-more-marco-eagle 2024-10-30T22:06:10+00:00 weekly 0.7 https://trial.medpath.com/news/new-england-journal-of-medicine-publishes-landmark-phase-iii-results-for-genentech-s 2024-10-30T21:19:54+00:00 weekly 0.7 https://trial.medpath.com/news/irhythm-technologies-receives-fda-510-k-clearance-for-design-modifications-to-its-zio 2024-10-30T21:19:52+00:00 weekly 0.7 https://trial.medpath.com/news/new-england-journal-of-medicine-publishes-landmark-phase-iii-results-for-genentech-s 2024-10-30T21:16:11+00:00 weekly 0.7 https://trial.medpath.com/news/huge-breakthrough-in-breast-cancer-drug-therapy-doubles-survival-time-the-independent 2024-10-30T21:11:29+00:00 weekly 0.7 https://trial.medpath.com/news/lexeo-therapeutics-scores-positive-early-data-for-apoe4-alzheimer-s-gene-therapy 2024-10-30T21:07:28+00:00 weekly 0.7 https://trial.medpath.com/news/breast-cancer-survival-time-doubles-with-three-drug-therapy-trial-finds-the-telegraph 2024-10-30T21:03:41+00:00 weekly 0.7 https://trial.medpath.com/news/wegovy-reduces-knee-pain-in-osteoarthritis-patients-with-obesity-study-finds-stat-news 2024-10-30T21:02:00+00:00 weekly 0.7 https://trial.medpath.com/news/medtronic-receives-fda-approval-of-mapping-and-ablation-system-and-catheter-daic 2024-10-30T20:56:23+00:00 weekly 0.7 https://trial.medpath.com/news/fda-advises-against-use-of-biozorb-markers-in-breast-cancer-and-other-indications 2024-10-30T20:51:11+00:00 weekly 0.7 https://trial.medpath.com/news/fda-receives-nda-for-3-month-version-of-leuprolide-mesylate-for-advanced-prostate-cancer 2024-10-30T20:51:10+00:00 weekly 0.7 https://trial.medpath.com/news/wave-life-sciences-highlights-growing-pipeline-at-research-globenewswire 2024-10-30T20:49:18+00:00 weekly 0.7 https://trial.medpath.com/news/risk-of-aria-e-in-donanemab-attenuated-through-new-enhanced-titration-method-of-delivery 2024-10-30T20:44:37+00:00 weekly 0.7 https://trial.medpath.com/news/neurovoices-anne-marie-morse-do-faasm-on-the-impact-of-the-once-nightly-sodium 2024-10-30T20:44:36+00:00 weekly 0.7 https://trial.medpath.com/news/azenta-obtains-regulatory-approval-for-clinical-long-read-whole-genome-sequencing-test 2024-10-30T20:33:46+00:00 weekly 0.7 https://trial.medpath.com/news/doctor-given-24-months-to-live-reveals-how-she-reversed-her-cancer-with-breakthrough-therapy 2024-10-30T20:19:31+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-abbott-cgms-for-use-during-medical-imaging-drug-delivery-business 2024-10-30T20:16:02+00:00 weekly 0.7